Obstructive Sleep Apnoea and Lipid Metabolism: The Summary of Evidence and Future Perspectives in the Pathophysiology of OSA-Associated Dyslipidaemia

Abstract

Obstructive sleep apnoea (OSA) is associated with cardiovascular and metabolic comorbidities, including hypertension, dyslipidaemia, insulin resistance and atherosclerosis. Strong evidence suggests that OSA is associated with an altered lipid profile including elevated levels of triglyceride-rich lipoproteins and decreased levels of high-density lipoprotein (HDL). Intermittent hypoxia; sleep fragmentation; and consequential surges in the sympathetic activity, enhanced oxidative stress and systemic inflammation are the postulated mechanisms leading to metabolic alterations in OSA. Although the exact mechanisms of OSA-associated dyslipidaemia have not been fully elucidated, three main points have been found to be impaired: activated lipolysis in the adipose tissue, decreased lipid clearance from the circulation and accelerated de novo lipid synthesis. This is further complicated by the oxidisation of atherogenic lipoproteins, adipose tissue dysfunction, hormonal changes, and the reduced function of HDL particles in OSA. In this comprehensive review, we summarise and critically evaluate the current evidence about the possible mechanisms involved in OSA-associated dyslipidaemia.

1. Introduction

Obstructive sleep apnoea (OSA) is common disorder which is characterised by recurrent collapses of the upper airways during sleep. Intermittent hypoxia (IH) and sleep fragmentation are the most important factors in the pathomechanism of OSA resulting in sympathetic overdrive, oxidative stress and systemic inflammation. These derangements lead to cardiovascular and metabolic alterations, such as atherosclerosis, hypertension, insulin resistance and dyslipidaemia, ultimately contributing to cardiovascular morbidity and mortality [1].

Dyslipidaemia is an independent risk factor for cardiovascular morbidity [2]. There is also strong evidence supporting the role of OSA with altered lipid profile: elevated triglyceride (TG), total cholesterol (TC) and low-density lipoprotein cholesterol (LDL-C) concentrations with a corresponding reduction in high-density lipoprotein cholesterol (HDL-C) levels were commonly found in patients with OSA [3,4]. Understanding the mechanisms linking OSA to lipid abnormalities is of major clinical importance, as they could represent treatable traits (i.e., choosing the right lipid-lowering medication and lifestyle changes), and also highlights the importance of active screening of dyslipidaemia in patients with OSA.

The aim of this review is to summarise and critically evaluate the current evidence about the possible mechanisms involved in OSA-associated dyslipidaemia. Naturally, we focus on human studies; however, we briefly discuss animal models and highlight if the research was conducted in humans or animals.

2. Overview of Physiological Lipid Metabolism

2.1. The Physiological Role of Chylomicrons

Dietary TGs are hydrolysed by several lipases (for example pancreatic and gastric lipases) to FFAs and monoacylglycerol (MAG) to be absorbed by the enterocytes in the small intestine [5]. FFAs can be transported by passive diffusion or fatty acid transporters, such as cluster determinant 36 (CD36) or fatty acid-transport protein 4 (FATP4). Dietary cholesterol esters (CEs) are hydrolysed to FFAs and free cholesterol (FC). Several FC transporters were identified on the enterocytes, such as the Niemann–Pick C1-like protein (NPC1L1), ATP-binding cassette protein G5 (ABCG5) and G8 (ABCG8) and scavenger receptor class B type I (SR-BI). They are also expressed in the apical membrane of hepatocytes [6].

The chylomicrons (CMs) are large TG-rich lipoproteins containing apolipoprotein B-48 (apoB-48) which are usually formed by dietary FFA absorbed from the small intestine [7]. The most common role of CMs is to transport dietary cholesterol and TGs to the peripheral tissues and to the liver; the process is called “exogenous lipid transport” (Figure 1). CMs have also an active role in enterohepatic cholesterol transport. Around 1000 g of biliary cholesterol is secreted to the intestine every day. Thus, the majority of CM-transported cholesterol derives from the reabsorption of biliary cholesterol [8].

CMs are synthetised in the endoplasmic reticulum (ER) and Golgi apparatus of the enterocytes. First, in the ER, the previously hydrolysed FFAs, FC and MAG are resynthesised. FATP4 converts FFAs to fatty acyl-CoA (FFA-CoA) [9], and thus FFA-CoA and MAG can be converted to diacylglycerol (DAG) by monoacylglycerol acyl transferase 2 (MGAT2) [10,11]. Then, diacylglycerol acyl transferase 1 (DGAT1) further converts DAG with FFA-CoA to triacylglycerol (TAG) [12], which is the main component of the nascent CM [10]. TAG can leave the ER to form cytosolic lipid droplets or chylomicrons. FC is transformed to CEs by the acyl-coenzyme A:cholesterol acyltransferase (ACAT).

Apolipoprotein B-48 (apoB-48) is a unique marker of CMs, and each CM particle contains one apoB-48 molecule [13]. ApoB-48 is a truncated form of the hepatic apolipoprotein B-100 (apoB-100), and it has 48% of the initial length of apoB-100 after a post-transcriptional mRNA modification in the intestine. The scaffolding of apoB-48 with TAG, CE and phospholipids is mediated by microsomal triglyceride transfer protein (MTP), resulting in primordial CMs. Primordial CMs can be expanded with further TG or CM by MTP or after the fusion with lipid droplets [14]. After the core expansion, apolipoprotein A-IV (apoA-IV) is also assembled into the nascent CM surface [15]. Nascent CMs are transported to the Golgi in pre-CM transport vesicles (PCTVs) [16,17] where apolipoprotein A-I (apoA-I) is also incorporated. Finally, a pre-CM leaves the enterocyte through its basolateral membrane by exocytosis.

In the circulation, a nascent CM gains further apolipoproteins, such as apoC-I, apoC-II, apoC-III and apoE from HDL [18], resulting in a mature CM. After hydrolysis of TAGs from CMs by lipoprotein lipase (LpL), the core of CMs is decreased. The remnant CM particles are taken up mainly by LDL receptors (LDLRs) of hepatocytes [19].

2.2. The Physiological Role of VLDL

Very-low-density lipoprotein (VLDL) delivers lipids from the liver to the peripheral tissues; this process is called “endogenous lipid transport” (Figure 1). VLDL is synthetised in the liver and regulated by the FFA influx. The FFAs originate from adipocytes, CM remnants and the intestine via the portal vein [20]. VLDL is composed of a TG-rich core (synthetised from FFAs) surrounded by FC, CE, phospholipids (PLs) and apolipoproteins (apoB-100, C, E).

ApoB-100 expressed by the liver is the essential component of VLDL, IDL and LDL particles. ApoB-100 is lipidated in the ER by MTP, resulting in primordial VLDL and then pre-VLDL particles [21]. Under inadequate TG availability, apoB-100 can be degraded in several ways (such as ER-associated degradation or post-ER presecretory proteolysis). Primordial VLDL can also fuse with microsomal lipid droplets associated with apoC-III [22]. Pre-VLDLs are transported to the Golgi in specialised vesicles (VLDL transport vesicles). During the Golgi-associated maturation of VLDL, apoB-100 undergoes conformational changes and VLDL is expanded by lipoproteins [23], and VLDL leaves the Golgi by exocytosis.

VLDL is metabolised by LpL to produce intermediate-density lipoproteins (IDLs) which can be taken up by the liver via apoE receptors [24]. IDLs can transfer apoE to HDL particles, avoiding hepatic clearance, and their TG content is hydrolysed by hepatic lipase (HL), resulting in CE-rich LDL particles. VLDL receptors (VLDLRs) can be found in several tissues such as adipose tissue, muscle and heart and recognise apoB-100 and apoE. They can bind VLDL, IDL or CM but not LDL particles [25].

2.3. The LDL Metabolism

LDL particles are the most important cholesterol carriers in the circulation (Figure 1). LDL consists of mainly CE, FC, TG, PL and a single molecule of apoB-100 [26]. The size, composition and density of HDL are mainly influenced by LpL and cholesteryl ester transfer protein (CETP) functions [27]. Several modified LDL particles were identified, such as oxidised LDL (oxLDL), small dense LDL (sdLDL) and desialylated LDL, which are strongly atherogenic [28,29,30]. Further subclasses can be identified by gel electrophoresis: large (LDL 1–2) and small (LDL 3–7) subfractions [31]. Circulating LDL particles are absorbed by the liver (70%) and peripheral tissues (30%), mainly by the LDL receptor (LDLR) [32].

LDLR binds apoB-100 and apoE with high affinity and is thus responsible for the uptake of VLDL, IDL and LDL particles [6]. The expression of LDLR is regulated via a negative feedback mechanism mediated by the complex of sterol-regulated transcription protein-2 (SREBP-2) and SREBP cleavage activating protein (SCAP) [33]. In cholesterol-depleted cells, the SREBP-2/SCAP complex is proteolytically cleaved in the Golgi, resulting in SREBP-2. SREBP-2 activates HMG-CoA reductase and LDLR, leading to cholesterol uptake [34,35]. On the contrary, high cellular cholesterol levels lead to conformational changes of SCAP in the ER not allowing the transport of the SREBP-2/SCAP complex to the Golgi [36]. LDLR can be regulated at the posttranscriptional level by proprotein convertase subtilisin/kexin type 9 (PCSK9) which degrades LDLR [37].

Other receptors can also eliminate LDL from the circulation. Low-density lipoprotein receptor-related protein-1 (LRP-1; also known as cluster of differentiation 91 (CD91)) is a multifunctional receptor expressed in several tissues (hepatocytes, adipocytes, muscle cells, macrophages and endothelial cells). Its expression is strongly regulated by metabolic and inflammatory processes [38]. LRP-1 receptors mediate the clearance of apoE-containing lipoproteins (VLDL and CM remnants) mainly in the absence of LDLR. In the lack of hepatic LRP-1, CM clearance is decreased [39]. Moreover, it also binds lipases, such as HL and LpL: they enhance the binding of apoE-containing lipoproteins to LRP [40,41]. LRP-1 plays a role in the HDL metabolism by enhancing the recycled apoE accumulation in early endosomes [42]. The presence of macrophages with LRP-1 deletion was associated with elevated plasma CE and TG levels resulting in the accumulation of circulating TG-rich lipoproteins [43]. Other studies demonstrated the atherogenic effects of LRP-1 as it can also mediate the accumulation of cholesterol in macrophages [43] or in cardiomyocytes [44]. Besides the lipid metabolism, LRP-1 internalises more than 100 ligands, including proteinases and proteinase-inhibitor complexes (tissue plasminogen activator (tPA), urokinase PA (uPA), matrix metalloproteases (MMPs)), coagulation factors, growth factors and matrix proteins (fibronectin, thrombospondin). LRP-1 is able to regulate several transcription factors (such as nuclear factor-κB (NF-κB)) affecting immune responses and tissue survival. In pathophysiological circumstances, LRP-1 can be shed by proteases, resulting in its soluble form (sLRP-1). During inflammation, sLRP-1 stimulates the expression of further pro-inflammatory cytokines, such as TNF-α [38]. However, other studies reported its anti-inflammatory function. sLRP1 mediates the internalisation of αMβ2 integrin, resulting in the inhibition of its adhesion properties [45]. In addition, sLRP-1 decreased the expression of TNF-α and IL-1 [46].

2.4. The Role of Lipoprotein Lipase

LpL hydrolyses the VLDL- and CM-associated TAGs to FFAs and MAGs which are taken up by the target cells. This enzyme is mainly produced by adipose tissue and skeletal and cardiac muscle and transported to the luminal surface of endothelial cells by the glycosylphosphatidylinositol-anchored high-density lipoprotein-binding protein 1 (GPIHBP1) [47]. This endothelial LpL pool is referred to as the functional LpL [48]. LpL activity is regulated by different physiological stimuli in a tissue-specific manner. In white adipose tissue, LpL activity is increased by the postprandial state and decreased by fasting [49]. On the contrary, fasting activates the myocardial LpL [50]. Finally, in skeletal muscle, LpL activity is promoted by acute exercise [51]. ApoC-II is the main cofactor of LpL activity [18], whereas apoC-I and apoC-III have been shown to inhibit LpL activity [52]. Moreover, some members of the family of angiopoietin-like proteins, such as ANGPTL3 (hepatocyte), ANGPTL4 (adipocyte) and ANGPTL8, also promote the inhibition of LpL [53,54]. Several hormones, such as insulin, glucocorticoids and adrenalin, stimulate LpL activity in the adipose tissue [6].

2.5. The Physiological Role of HDL

HDL is a major mediator in reverse cholesterol transport (RCT). RCT is termed as a cholesterol transport from the peripheral cells (including macrophages) back to the hepatocytes for further metabolism [55]. In general, HDL particles comprise a hydrophobic core with CE and TG covered by PL, FC and apolipoproteins (apoA-I, A-II, A-IV, A-V, C-I, C-II, C-III, E, F, J, M). Various HDL particles highly differ in their size, shape, proportion of proteins and lipids and biological activities [56]. The two main forms of HDL are the small and poorly lipidated discoid HDL (also known as preβ-HDL) and the larger and CE/TG-containing spherical HDL (also known as α-HDL) [56,57]. Spherical particles represent the majority of HDL particles in the circulation [57]. HDL₂ particles are larger and lipid-rich but less dense, and HDL₃ particles are smaller, lipid-poor and dense [58]. These can further be divided into HDL3c, HDL3b, HDL3a, HDL2a and HDL2b fractions [57]. Further subclasses can be identified by gel electrophoresis: large (HDL 1–3), intermediate (HDL 4–7) and small (HDL 8–10) subfractions [31]. The small HDL 8-10 particles are atherogenic through easy penetration to the endothelium and low recognition by HDL receptors [59,60].

The main structural apolipoproteins of HDL are apoA-I (70%) and apoA-II (20%) [61]. ApoA-I plays role in activating LCAT and also has anti-inflammatory and antioxidant effects [62,63]. ApoA-II is an important inhibitor of LpL directly and indirectly by replacing apoC-II in VLDL. Moreover, it also has a cofactor activity for LCAT and CETP [64]. ApoM accounts for approximately 5% of HDL proteins. It plays role in lipid transfer into nascent HDL [65] and enhances the cholesterol efflux from foam cells [66]. Noteworthily, apoM is a carrier of sphingosine-1-phosphate (S1P) mentioned below [67]. Other apolipoproteins constitute a minor amount of HDL, such as apoA-IV, V, C-I, C-II, C-III, D, E, J and L [68]. It is important to note that apoJ or clusterin has anti-apoptotic, anti-atherogenic and anti-inflammatory properties and is involved in lipid transport forming HDL particles [69].

ApoA-I is mainly produced by the liver (70%) [70] and partly by the intestine (30%) [71]. Lipid-poor apoA-I binds ATP-binding cassette transporter A1 (ABCA1) on peripheral cells (such as hepatocytes and macrophages [72]), resulting in FC and PL transport from the cells to apoA-I [73]. Two apoA-I molecules with FC and PL form a discoidal HDL formation [57]. Noteworthily, these particles can also be produced from surface components of the catabolism of TG-rich lipoproteins after the LpL hydrolysis [56]. The discoidal HDL formation reacts quickly with lecithin cholesterol acyltransferase (LCAT) which transports free acid from lecithin to FC, resulting in CE. After esterification and incorporation of more apoA-I by LCAT, the HDL particle becomes a mature spherical form (small HDL₃, large HDL₂) [55,57] which is dynamically modified in the RCT. Phospholipid transfer protein (PLTP) transfers more PL and FC from VLDL to HDL, enhancing the LCAT reaction and resulting in HDL₂ with increased size [74]. PLTP can lead to the fusion of HDL particles with a consequential production of small lipid-poor apoA-I/PL complexes [75].

The mature HDL particles can be cleared from the circulation by two main pathways: (1) The main receptor in the RCT is SR-BI, which is expressed on hepatocytes and steroidogenic cells. SR-BI has an affinity for CE and apoA-I content in HDL particles [76,77]. The hepatic HDL uptake is stimulated by HL [78]. (2) The other mechanism is the indirect pathway in which spherical HDL particles are modified by CETP. CETP is mainly produced by hepatocytes and adipocytes and circulates with HDL [79]. CETP transports CE from HDL towards apoB-containing lipoproteins (mainly LDL, but also VLDL and CM) in exchange for TG in the opposite direction. The transfer activity of CETP is regulated by the triglyceride levels [80]: in the physiological state, predominantly CEs are transported from HDL to apoB-containing lipoproteins with a minor transfer of TG in the opposite direction. In hypertriglyceridaemia, increased concentrations of apoB-containing lipoproteins are available as potential acceptors for CEs. Moreover, CETP also transports TG from TG-rich lipoproteins (VLDL, CM) to LDL and HDL, resulting in small, dense and TG-rich particles [80]. The TG and PL content of these HDL₂ particles can be further hydrolysed by HL, resulting in lipid-poor small HDL₃ particles which interact with ABCA1 for the next HDL circle [56,78]. The CE content of the apoB-containing particles is taken up by the hepatic LDLR.

It is important to mention that by taking cholesterol from foam cells, HDL has a protective role against atherosclerosis [81,82,83]. HDL also inhibits LDL oxidation. Small HDL₃ particles are more resistant to oxidative damage than HDL₂ particles and inactivate the products of LDL lipid peroxidation [84,85]. Several HDL-associated apolipoproteins [56] and HDL-bound paraoxonase-1 (PON-1) possess antioxidant properties [86]. HDL displays anti-inflammatory effects by decreasing the expression of inflammatory cytokines and adhesion molecules and inhibiting inflammatory cell activation [87,88].

3. Current Knowledge of The Pathophysiological Lipid Metabolism in OSA

3.1. Animal Models

Animal models allow experimental investigation of OSA-related processes in isolation and have been extensively used to explore the relationship between dyslipidaemia and OSA. The effects of IH were the most widely investigated [89]. These models allow researchers to precisely define the major parameters of IH, such as the frequency or the severity of the hypoxic events [90]. However, it is important to consider that experimental IH episodes cause hypoxia in animals that is significantly more severe than that experienced in humans. For a realistic stimulation of IH, SaO₂ should be much lower in mice than the SaO₂ observed in patients [90]. Most of the experimental studies investigated whether IH regulates the expression of different transcription factors involved in the lipid metabolism. The regulation of hypoxia-inducible factor-1 (HIF-1), SREBP-1 and stearoyl-coenzyme A desaturase 1 (SCD-1) was investigated in detail in rat and mouse models [91,92,93]. The consequences of dyslipidaemia, such as atherosclerotic lesions associated with IH, can also be studied more precisely in animal models [94].

In humans, IH and sleep fragmentation are closely interrelated [95], and animal models could better separate these entities. On the other hand, dyslipidaemia in humans is complicated by genetic factors, diet, exercise, abdominal obesity, the presence of comorbidities and medications. Therefore, complex animal models which study numerous heterogeneous processes simultaneously are warranted [94].

3.2. Calorie Intake in OSA

Excessive calorie intake is a main cause of aberrant obesity, which is the most important risk factor for OSA. Indeed, patients with OSA tend to consume high-calorie diets [96]. Hunger and food intake are controlled by the balance of a number of hormones, such as leptin, ghrelin, insulin, cholecystokinin, glucagon-like peptide 1 (GLP-1) and peptide YY [97]. However, increased levels of GLP-1 and gastric inhibitory polypeptide/glucose-dependent insulinotropic polypeptide were found in patients with OSA [98]. Moreover, IH seemed to upregulate the expression of peptide YY, GLP-1 and neurotensin in enteroendocrine cells [99]. These hormones have an anorexigenic influence on the enteric nervous system. As a vicious circle, sleep fragmentation in OSA attenuates hypothalamic leptin receptors, resulting in cravings for high-energy foods [100]. The consequences of this leptin resistance are an increase in fat mass and gaining weight, worsening obesity [100]. The ingested fat is the main drive of CM production [101] leading to further alterations in the lipid profile.

3.3. Intestinal Lipid Absorption in OSA

OSA is associated with postprandial hyperlipidaemia [102]. Indeed, using oral retinyl-palmitate, the retinyl-esters incorporated into CM had an earlier peak under IH than under normoxia [103]. Although patients with OSA have higher postprandial TG levels, experimental IH in this group did not result in a further increase in TG levels [104].

High postprandial TG levels could be due to accelerated intestinal absorption. For instance, the FFA transporter CD36 is upregulated by HIF-1 [105]. However, CD36 expression is also upregulated by the peroxisome proliferator-activated receptor-gamma (PPAR-γ), the expression of which was reported to be decreased in OSA [106]. Nevertheless, intrahepatic CD36 was increased in mice exposed to IH [107].

Bile acids act as natural detergents: they emulsify lipid dietary fat into smaller lipid droplets, making the digestion by lipases easier. Cytochrome P450 7A1 (CYP7A1), an important enzyme in bile acid synthesis, was repressed by HIF-1α under hypoxia, suggesting altered bile acid production [108]. However, the effects of IH on bile acid synthesis and absorption have not been investigated. Similarly, gastric and pancreatic lipases were not studied in OSA.

3.4. Impaired Intravascular Lipolysis and Uptake by the Periphery: Lpl Dysfunction in OSA

A well-described mechanism for OSA-associated hyperlipidaemia is the impaired clearance of circulating lipoproteins by LpL (Figure 2). Drager et al. showed that the functional clearance rate of CEs and TGs was significantly lower among patients with OSA compared to controls [103]. This delayed clearance was correlated with the depth of nocturnal hypoxaemia (MinSatO₂) and disease severity (apnoea–hypopnoea index (AHI)) [109]. In human preadipocytes exposed to 24 hours of hypoxia in vitro, a 6-fold decrease in LpL activity was detected [110]. Serum LpL concentrations were lower in patients with OSA compared to controls and negatively correlated with disease severity [111].

Several OSA-associated mechanisms can lead to the altered function of LpL, including IH, oxidative stress, inflammation, catecholamines and hormones. IH itself is a potent inhibitor of LpL [103], and the degree of hypoxia correlates with the delay in TG clearance [112,113]. Serum LpL concentrations correlated with markers of nocturnal hypoxia, such as the oxygen desaturation index (ODI) [114] and nocturnal SpO₂ [111]. In animal models of OSA, CIH increased the levels of adipose ANGPTL4 in an HIF-1α-dependent manner [103], and ANGPTL4 levels correlated with the severity of nocturnal desaturation [115]. Moreover, the antibody against ANGPTL4 increased the activity of LpL in the adipose tissue and the lung [112]. However, Mahat et al. failed to demonstrate any differences in postprandial LpL activity or ANGPTL4 expression between normoxia and IH [110], suggesting other, ANGPTL-4-independent, regulatory mechanisms during CIH [112]. In vivo, higher concentrations of plasma ANGPTL4 and ANGPTL8 were measured in patients with OSA compared to the controls [116]. Higher serum levels of ANGPTL3 were detected in patients with OSA and coronary artery disease (CAD) compared to the patients having OSA alone [117].

PPAR-γ is a main regulator of several genes associated with lipid metabolism, including LpL [118], and it is downregulated by hypoxia in an HIF-1α-dependent manner [119]. Jun et al. detected that acute hypoxia decreased the PPAR-γ expression, resulting in downregulated LpL in mice [113]. However, hypoxia had no effect on the expression of GPIHBP1, which is the carrier of LpL [113].

Inflammation was also found to impair the function of LpL in several ways. Interleukin-1 (IL-1) and tumour necrosis factor-α (TNF-α) decrease the activity of LpL in vitro [120,121] and in vivo [122], at transcriptional [123] and post-transcriptional levels [124]. Circulating LpL levels inversely correlated with CRP levels, emphasising the inhibitory role of inflammation in LpL function [111].

OSA is characterised by increased sympathetic activity [125]. Early studies indicate that catecholamines reduce LpL activity directly [126,127] and indirectly through the activation of ANGPLT4 [128].

Insulin activates LpL in the adipose tissue [129] and downregulates the expression ANGPTL3 [130]. However, insulin resistance (IR) decreases the activity of LpL. In line with this, HOMA-IR, the marker of IR, negatively correlated with LpL [111]. Leptin decreases the activity of LpL directly [131] and indirectly by decreasing the expression of ANGPTL3 [132]. Leptin levels were elevated in OSA [133]. Decreased levels of adiponectin, detected in OSA [134], were associated with lower LPL activity independently of systemic inflammation [135].

In conclusion, impaired function of LpL in OSA leads to decreased lipid uptake of the peripheral tissues resulting in an increase in circulating CM and VLDL-C levels.

3.5. Alternative Ways Leading to Decreased Lipid Uptake

In OSA, LRP-1 can be downregulated by SREBP-1 [136] in an FFA- [137] or IH-dependent fashion [138]. Moreover, vitamin D [139] and klotho [140], which both increase LRP-1 expression, are decreased in OSA [141,142]. The shedding of LRP-1 is facilitated by pro-inflammatory cytokines [38] or atherogenic lipoproteins [143], resulting in its soluble form (sLRP-1) which can be measured in the circulation; sLRP-1 was decreased in OSA and correlated with disease severity [144].

3.6. Increased Lipid Production in the Liver

The lipid production in the liver is influenced by three main mechanisms: (1) de novo lipogenesis of the hepatocytes, (2) FFA delivery and uptake from the periphery and (3) availability of lipids and carbohydrates.

Previous evidence suggested that IH activates SREPB-1, the key transcriptional factor involved in lipid biosynthesis, through HIF-1α activation [91,92]. SREBP-1 upregulates SCD-1. SCD-1 is responsible for the synthesis of monosaturated FAs (MUFAs) [93], which are substrates for PL, TG and CE synthesis [145]. As mentioned above, the HIF-1α/SREBP-1/SCD-1 pathway was widely investigated in OSA (Figure 2). Mice with partial HIF-1α-deficiency exhibited lower hepatic mRNA and protein levels of SCAP and SCD, lower hepatic protein levels of SREBP-1 and lower hepatic fat accumulation compared to the wild-type mice [92]. In a SCAP-deficient mouse model, 5 days of IH did not influence the levels of serum and hepatic lipids and expression of SREBP-1, SCD-1 and HMG-CoA-reductase [138]. Furthermore, SCD-1 deficiency in mice abolished the IH-induced increased hepatic SCD-1 and plasma VLDL-C levels and atherosclerosis in the ascending aorta [146].

The duration of IH seems to influence lipid production in OSA. Five days of IH exposure increased the serum levels of total cholesterol, HDL-C, PL, TG, hepatic TG and SREBP-1 and the protein and mRNA levels of SCD-1 [91]. However, the genetically obese leptin-deficient rats that had higher baseline lipid values did not show changes in serum lipid profile after 5 days of IH compared to the lean rats. The authors concluded that short-term IH upregulates lipid biosynthesis but does not affect it in the presence of pre-existing lipid alterations [91]. On the contrary, genetically obese rats exposed to 12 weeks of IH experienced elevated TG and PL levels as well as SREBP-1 and SCD-1 transcription [147].

The severity of IH may also affect lipid production. The ubiquitination of HIF-1α leads to the proteasomal degradation of HIF-1α protein and depends on the O₂ tension [148,149]. In the study of Li et al., only severe IH (oxygen nadir of 5% compared to 10%) increased the hepatic SCD-1 levels [3]. The authors hypothesised that moderate IH did not prevent HIF-1α from proteasomal degradation [3]. In addition, oxidative stress contributes to hepatic lipid overproduction in two ways. Firstly, reactive oxygen species (ROS) stabilise HIF-1α [150]. Secondly, ROS induce lipid peroxidation in the liver [3]. Lipid peroxidation leads to hepatic inflammation and fibrosis resulting in nonalcoholic steatohepatitis (NASH) [151]. The pathomechanism of NASH in OSA was reviewed in detail previously by Mesarwi et al. [151].

IH also enhances hepatic lipid production through the increased sympathetic tone which has a stimulatory effect on VLDL secretion [152].

However, IH alone did not seem to be enough to cause dyslipidaemia in animal models. In atherosclerosis-resistant mice (C57BL/6J), atherosclerosis was observed only in those exposed to both IH and cholesterol-rich diet, but not in those exposed to cholesterol-rich diet or to IH alone [94]. Moreover, the combination of IH and a cholesterol-rich diet was associated with a marked progression of dyslipidaemia. The authors suggested that the presence of dyslipidaemia due to genetic or environmental factors is required for atherogenic consequences of CIH [94].

In line with this, twin studies showed genetic susceptibility to the development of dyslipidaemia [153] and OSA too [154]. In our previous twin study, we detected a heritable relationship between TG levels and sleep parameters (AHI, ODI, TST90%), suggesting a common genetic background [155]. The genetic link between OSA and TG levels has recently been confirmed in a genome-wide association study [156]. Most notably, dyslipidaemia and OSA share common genetic loci, such as PPAR-γ [157,158] or APOE polymorphism [159].

The hepatic lipid accumulation and hepatic insulin resistance can enhance the lipid alterations in OSA. The hepatic lipid accumulation is the consequence of the FFA overload from the periphery due to adipose tissue dysfunction with increased lipolysis and altered lipid clearance by LpL. The coexistence of insulin resistance may also increase VLDL production. In insulin resistance, insulin loses the ability to promote the degradation of apoB [160]. The accumulated lipid content undergoes lipid peroxidation under IH leading to NASH [151]. Moreover, the lipid overproduction leads to increased VLDL production and export to the circulation.

3.7. Abnormal Modifications of LDL in OSA

LDL modification is one of the most important consequences of oxidative stress and inflammation. LDL can be modified in the extracellular space or in the lysosome of macrophages [161] by enzymatic (such as myeloperoxidase (MPO)) and non-enzymatic (such as desialylation, glycosylation, interaction directly with ROS) mechanisms. Not only the lipids but also the protein components of LDL can be modified [162]. Small dense LDL (sdLDL) particles associated with hypertriglyceridaemia are often desialylated, which is the most frequent modification of LDL. Due to their decreased affinity for LDL-R, their longer circulation time makes them susceptible to other modifications [163], including glycosylation [164] and oxidation [165]. Oxidised LDL (oxLDL) particles were found to have pro-inflammatory and atherogenic potential contributing to atherosclerosis (Figure 3). OxLDL particles can be hydrolysed by PON-1 associated with HDL [166].

Pro-atherogenic sdLDL3–7 subfractions were significantly higher in the OSA group [31]. SdLDL particles were independently associated with OSA in non-obese participants [167]. LDL size was independently associated with metabolic syndrome in OSA [168]. However, Liu et al. did not detect a correlation between OSA severity measures and sdLDL [169].

Only a few studies investigated oxLDL in OSA; oxLDL levels were found to be increased in OSA in most [170,171,172,173] but not all studies [174,175]. A recent meta-analysis concluded that oxLDL levels are increased in OSA [176]. However, studies that matched in age or BMI between patients with OSA and controls showed no significant difference in oxLDL levels [176]. Furthermore, endothelial lectin-like oxidised low-density lipoprotein receptor-1 (LOX-1) was upregulated in OSA [172]. LOX-1 is the main receptor for oxLDL on endothelial cells and orchestrates the expression of adhesion molecules and may induce atherosclerosis in OSA [177].

3.8. HDL Dysfunction in OSA

HDL is converted to a dysfunctional form with impaired physiological effects due to IH, oxidative stress and inflammation [178] (Figure 3). The dysfunctional HDL comprises lower CE, oxidised PL, increased TG and decreased apoA-I content, serum amyloid A (SAA) and several inflammatory proteins, such as complement C3 [178,179].

There is some evidence that IH and inflammation [180] downregulate molecules in the RCT, such as ABCA1 [181] and SR-BI [91]. Short-term IH (5 days) decreased liver SR-BI protein levels independent of obesity in a mouse model. However, obese mice had lower baseline SR-B1 levels than lean mice [91]. On the contrary, long-term IH (4 weeks) did not cause a change in hepatic SR-B1 levels [3].

Oxidative stress enzymes associated with OSA [182], such as MPO, excessively oxidise HDL. The oxidative modification of apoA-I leads to its inability to interact with ABCA-1, resulting in decreased premature HDL and impaired cholesterol efflux [183,184]. Other oxidised components of HDL, such as oxidised PLs [185] or FFAs [186], can also impair the functions of apoA-I by destroying its structure [187]. Although the functionality of apoA-I seems to be altered, its levels were not affected in OSA [171]. Decreased activity of PON-1 is also associated with HDL dysfunction [188]. Circulating levels of PON-1 were lower in subjects with OSA than in controls [189,190,191,192,193].

Modified apoA-I is also not able to activate LCAT, leading to impaired RCT [194]. Moreover, oxidised HDL, through activating the NF-κB pathway [195], increases the expression of pro-inflammatory molecules, such as the adhesion molecule vascular cell adhesion molecule-1 (VCAM-1) [177]. Circulating SAA, the levels of which were elevated in OSA [196], dislocates apoA-I from HDL [197]. This SAA-rich HDL is unable to interact with ABCA-1 [198]. High calorie intake also attenuates the anti-inflammatory functions of HDL [199].

The higher levels of apoJ or clusterin in OSA [200,201] may suggest its protective function in the HDL metabolism.

Several studies evaluated the circulating HDL-C concentrations in OSA and reported decreased HDL-C levels in most [202,203] but not all cases [31]. In the study of Tan et al., OSA-associated HDL dysfunction was measured as reduced LDL oxidation by HDL [171]. Patients with OSA presented a higher degree of HDL dysfunction with a consequential higher concentration of oxLDL independent of cardiovascular comorbidities. HDL dysfunction was more strongly correlated with disease severity than HDL-C concentration [171]. In another study, HDL₂ and HDL₃ levels were correlated with IR, but not with OSA severity or the degree of hypoxia. The authors concluded that IR plays a role in OSA-related dyslipidaemia [169]. In a recent study, despite similar HDL-C levels between the OSA and control groups, the participants with OSA had higher pro-atherogenic small HDL 8-10 subfractions and decreased anti-atherogenic large HDL 1-3 subfractions [31]. Moreover, not only OSA severity but also sleep fragmentation was inversely correlated with HDL-C and HDL 1-3 subfractions [31].

The atherogenic index of plasma (AIP) is a biomarker of atherosclerosis and coronary heart disease which is calculated as log(TG/HDL-C) [204] and reflects the dysregulation between anti- and pro-atherogenic lipoproteins. Previous studies found significantly higher AIP values among participants with OSA compared to the controls [205,206,207,208,209]. AIP was higher in patients with OSA and associated with disease severity [206,207,209] and daytime sleepiness in some [209] but not all studies [208].

3.9. Increased Intracellular Lipolysis in Adipose Tissue

Fatty acids are mainly stored in the form of TAG in adipocytes [210]. This storage can be mobilised in three main steps: (1) Adipocyte triglyceride lipase (ATGL) catalyses the hydrolysis of TAG to DAG and FFAs [211]. (2) The hydrolysis of DAG is catalysed by hormone-sensitive lipase (HSL), resulting in MAG and FFAs [212]. (3) Finally, monoacylglycerol lipase (MGL) completes the hydrolysis, producing FFAs and glycerol [213].

Dysregulated peripheral lipolysis has been associated with OSA (Figure 2). IH leads to increased sympathetic activity [214], and elevated levels of catecholamines are major activators of lipolysis [215]. In healthy subjects, increased sympathetic tone with consequential higher HSL expression was detected after two weeks of IH [216]. In mice, IH-induced lipolysis and decreased adipocyte size were detected [217]. In line with this, IH resulted in an increase in lipolysis rate by 211% and a decrease in intracellular lipid stores by 37% in human adipocytes too [218]. However, IH did not seem to affect postprandial lipolysis in lean healthy men [110].

Oxidative stress stimulates both HSL [219] and ATGL [220]. Moreover, several lipolysis-stimulating cytokines, such as TNF-α [221] and IL-6 [222], are detected in increased concentrations in OSA [223,224].

Endothelin-1 (ET-1) is upregulated by IH and induces lipolysis through the phosphorylation of HSL [225]. Fatty acid binding protein-4 (FABP-4) facilitates lipolysis by binding HSL [226], and its levels were detected in elevated concentration in OSA [227,228,229]. FABP-4 also interacts with a co-activator of ATGL, enhancing TAG hydrolysis [230].

Obesity is associated with higher basal levels of lipolysis [231]. Leptin exerts lipolytic activity [232], whilst adiponectin has an inhibitory effect on catecholamine-induced lipolysis [233]. In line with this, increased levels of leptin [234] and decreased levels of adiponectin [235] were reported in OSA.

Insulin is the main negative regulator of lipolysis. Insulin resistance is associated with the loss of the suppressive effects of insulin [236]. Moreover, the anti-lipolytic effect of insulin depends on the O₂ tension of adipose tissue [237]; in hypoxia, it seems to be inhibited [238].

It is important to note that fragmented sleep leads to the nocturnal secretion of adrenocorticotropin and cortisol [239], which enhance lipolysis [240].

4. Further Mechanisms in OSA-Associated Dyslipidaemia

4.1. Adipose Tissue Dysfunction

Obesity is the most important risk factor for OSA. At least 30% of obese patients have OSA, and 60% of the patients with OSA are obese [241,242]. The dysfunction of adipose tissue is an important contributor to the metabolic consequences of OSA [243]. White adipose tissue (WAT) is the most important energy storage. High levels of circulating FFAs force WAT to store lipids via two mechanisms: through increases in the number (hyperplasia) and the size (hypertrophy) of the adipocytes [244]. In contrast to hyperplasia, hypertrophy induces pathological changes in the adipose tissue by activating stress pathways, such as endoplasmic reticulum stress, oxidative stress and inflammation [245]. IH induces specific changes in WAT even in the absence of obesity [246]. However, adipocyte hypertrophy and hyperplasia are not always present in IH-induced adipose tissue dysfunction. Some previous studies detected shrunken adipocytes in the WAT of non-obese mice exposed to IH [247,248]. Moreover, IH reduced fat mass by inducing lipolysis [217]. Whereas the morphological changes of WAT are different between IH and obesity, they share the consequential abnormalities.

4.1.1. Inflammation in Adipose Tissue

The larger size of adipocytes reduces the vascularity of hypertrophic adipose tissue, resulting in lower oxygen tension and hypoxic damage. The consequential hypoxia contributes to inappropriate angiogenesis mediated by vascular endothelial growth factor (VEGF) [249]. Furthermore, IH activates HIF-1α and NF-κB, consequently resulting in an increased production of cytokines and adipokines [243].

In contrast to the healthy state characterised by anti-inflammatory immune cells, such as M2 type macrophages, T-helper 2 (Th2) cells, regulatory T cells and anti-inflammatory mediators (IL-10 or adiponectin), hypertrophic WAT is infiltrated by pro-inflammatory immune cells, mainly by CD8+ cytotoxic T cells and Th1 cells leading to the production of pro-inflammatory cytokines (TNF-α, IL-6) [246]. Moreover, hypoxic and inflammatory changes result in macrophage polarisation from M2 type to M1 type. In lean mice exposed to IH, reduced M2-type and increased M1-type macrophage infiltration were also detected in adipocytes [250]. M1-type macrophages enhance the inflammation, producing further cytokines, such as monocyte chemoattractant protein-1 (MCP-1). MCP-1 is an important regulator of macrophage tissue infiltration and chemotaxis of monocytes [251]. Moreover, it is secreted from adipose tissue to the circulation and may increase the hepatic expression of SREBP-1 [251]. Increased plasma levels of MCP-1 were detected in patients with OSA irrespective of obesity and correlated with ODI [252,253]. Furthermore, in the presence of IH, human adipocytes have a higher sensitivity to express pro-inflammatory genes [254].

4.1.2. Role of Adipokines

Leptin is a master regulator of food intake and body energy balance, and its levels were shown to be increased in obesity [255], diabetes [256] and cardiovascular diseases [257,258]. Leptin levels were widely investigated in OSA and found to be increased [133,259,260,261,262,263] even after adjustment for obesity [261]. OSA-associated hyperleptinaemia was related to disease severity measures, such as AHI [133,235,259,260], TST90% [235] and MinSatO₂ [261,264]. However, high levels of leptin contribute to leptin resistance by downregulating its cellular responses [265]. Leptin resistance with the loss of physiological functions of leptin also plays a role in OSA-associated metabolic alterations [266]. In a recent animal model, leptin injection did not decrease the food intake of rats exposed to IH [267]. Moreover, IH resulted in a reduced expression of leptin receptors, suggesting the role of leptin resistance in OSA [267,268]. Sleep fragmentation attenuates leptin signalling in the hypothalamus, resulting in consequential high-calorie food intake enhancing obesity [100]. However, sleep fragmentation itself was not found to influence circulating leptin levels [269]. Obese patients with OSA have dysfunctional adipose tissue with adipocyte hyperplasia which increases leptin production [270]. Independently of obesity, IH can itself induce leptin secretion via activating the sympathetic nervous system, renin–angiotensin system and hypothalamic–pituitary–adrenal axis [246,266]. Moreover, leptin gene expression is induced by HIF-1α [271].

Leptin may contribute to lipid alterations in OSA. Leptin activates hepatic lipid production [152] and peripheral lipolysis [232] through the activation of the sympathetic nervous system and by increasing the expression of SREBP-1 and SCD-1 [272]. Moreover, it decreases the activity of LpL [131]. The dissociation between high leptin levels and its action is caused by leptin resistance and attenuated leptin signalling in the liver [273]. A recent study found that leptin levels in OSA correlated positively with TG and negatively with HDL-C concentrations [274]. Leptin can lead to oxidative stress by activating the nicotinamide adenine dinucleotide phosphate (NADPH) oxidase [275].

Adiponectin is another important adipokine with anti-inflammatory and antioxidant properties, and its levels are inversely correlated with various disorders, such as obesity [276] and hypertension [277]. Lower adiponectin levels were detected in patients with OSA compared to controls [134,278] and were correlated with disease severity independently of obesity [279]. However, some studies found comparable [280] or even higher [274] adiponectin levels in patients compared to controls. IH suppresses adiponectin expression directly and indirectly by increased sympathetic activation [281]. Adiponectin increases the production of apoA-I and ABCA1 and induces HDL assembly [282,283]. It positively correlates with HDL-C levels independent of obesity [284]. Adiponectin enhances the catabolism of VLDL by activating LpL [285]. Moreover, it increases the mRNA levels of the VLDL-R in skeletal muscle cells [286]. In line with this, there is a negative correlation between VLDL-C and adiponectin levels [287].

Another anti-inflammatory and antioxidant adipokine is omentin, the levels of which were detected in lower concentrations and correlated positively with HDL levels in OSA [280].

4.2. Altered Hormone Production

Several other hormones have an impact on the lipid metabolism, such as cortisol [288], growth hormone (GH) [289] and insulin [290]. GH deficiency is known to be associated with lipid alterations [291], and GH levels were decreased in OSA [292]. Cortisol overproduction is strongly associated with dyslipidaemia [293], and its levels were detected in high concentrations in OSA [294]. Insulin activates LpL in the adipose tissue [129] and inhibits lipolysis [236]. Moreover, it promotes the degradation of apoB [160], leading to decreased hepatic production of apoB-containing lipoproteins. As OSA is associated with insulin resistance, these effects are mitigated.

4.3. Sleep Stages

It is known that rapid eye movement (REM) sleep is associated with higher sympathetic tone [295]. REM and non-REM (NREM) sleep influence the production of several hormones, such as cortisol [296] and GH [297]. GH is mainly produced during N3 sleep [297]. Some patients have a disproportionally higher burden of obstructive events in REM than in non-REM sleep. These patients have a higher risk for hypertension, diabetes and cardiovascular disease [298].

Only a few studies investigated the association between sleep stages and OSA. Interestingly, AHI measured in the REM phase (AHIREM) correlated with TG levels only in one study [299], and it did not have any correlation with lipid parameters in another study [300]. Xu et al. found an independent association between AHIREM and increasing levels of TG, HDL-C and apoE. However, this association became insignificant after analysing only the patients who had an AHINREM or AHIREM < 5/h [301]. In contrast, AHINREM correlated with TG, apoB [299,301], HDL-C, apoA-I [299], LDL-C and cholesterol levels [301]. Slow wave sleep duration and REM latency were independently and inversely associated with cholesterol and LDL-C levels [302]. In conclusion, it could be postulated that NREM sleep may have the greatest impact on lipid alterations in OSA.

5. Direct Consequences of Dyslipidaemia

5.1. Endothelial Dysfunction

Endothelial dysfunction is defined as an impairment in the vasodilatory ability of the vessels (mainly due to the compromised nitric oxide (NO) availability) leading to altered oxygenation, oxidative stress, vascular inflammation and consequential atherosclerosis. IH has a direct detrimental effect on endothelial function [303,304,305,306,307]. OxLDL particles also impair eNOS function by decreasing its expression [308], decreasing L-arginine availability [309]. Moreover, oxLDL increases iNOS expression and ROS generation [308].

5.2. Systemic Inflammation and Consequential Atherosclerosis

OxLDL particles increase the levels of adhesion molecules (VCAM-1, P-selectin) on the endothelium, resulting in enhanced leukocyte recruitment [310]. In OSA, these molecules are also overexpressed by IH and oxidative stress in an NF-κB-dependent fashion [311,312,313]. This leads to increased adhesion between leukocytes and endothelium cells, resulting in the adhesion of circulating leukocytes to the endothelium and slowing down the rolling of leukocytes, thus facilitating their extravasation [314]. Moreover, the oxLDLs have a greater affinity for scavenger receptors, such as LOX-1 on endothelial and smooth muscle cells [315] and CD36 on macrophages [316]. Thus, the activated macrophages increase their CD36 expression, facilitating uncontrolled oxLDL uptake [317], and release pro-inflammatory cytokines (IL-1, TNF-α) [318]. This activation of innate immunity is a key mechanism in foam cell formation in atherosclerosis. It is important to know that adaptive immune cells, such as B-cell-derived plasma cells, are also activated and produce antibodies against oxLDL, and antigen-specific T cells produce further cytokines, resulting in enhanced inflammation [319].

HDL dysfunction in OSA also contributes to atherosclerosis [87,88]. The anti-inflammatory and anti-atherogenic effects of HDL are mainly mediated by sphingosine-1-phosphate (S1P). S1P decreases the expression of several inflammatory cytokines (such as TNF-α) and increases the expression of eNOS [320], improving endothelial function [321]. Elevated S1P enrichment was found in HDL₃ particles [322]. HDL particles also enhance the eNOS function by binding to SR-BI expressed on endothelial cells [323]. HDL is an important inhibitor of platelet activation and aggregation as well as of coagulation factors, such as factor X and tissue factor [324].

5.3. Insulin Resistance

Dyslipidaemia can cause insulin resistance. Increased FFA levels due to increased lipolysis reduce insulin-mediated glucose uptake in skeletal muscle by interrupting insulin signalling [325]. Moreover, FFAs activate the NF-κB pathway, resulting in the production of pro-inflammatory cytokines such as TNF-α, IL1β and IL6 in the peripheral tissues. Systemic low-grade inflammation reduces the responsiveness of the peripheral tissues to insulin, leading to insulin resistance [326].

6. The Effect of OSA Therapy on the Lipid Metabolism

6.1. The Effect of CPAP Therapy

Continuous positive airway pressure (CPAP) is the gold standard treatment for OSA [327]. Several studies investigated the effect of CPAP on plasma or serum lipid profile in OSA. Various duration of CPAP (i.e., from 8 weeks to 6 months) effectively decreased TG, TC, LDL-C and apoB and increased HDL-C levels [328,329,330,331,332]. However, these effects depended on sufficient therapy adherence in some cases [331]. On the contrary, some studies failed to demonstrate improvement in lipid levels; the TG, TC and HDL-C levels did not change after 6 weeks to 4 months of CPAP therapy [333,334,335,336].

The effect of CPAP therapy on the lipid profile was also investigated in meta-analyses. Nadeem et al. evaluated 29 articles including 1958 participants with therapy durations ranging from 2 days to 1 year [337]. They concluded that there was a significant reduction in TC (−5.66 mmol/L) and LDL-C (−0.49 mmol/L) levels; however, TG levels did not change (−0.05 mmol/L). HDL-C levels increased after the therapy (+0.21 mmol/L) [337]. Xu et al. analysed the results of six studies including 456 subjects with therapy durations of 2–24 weeks [338]. CPAP therapy sufficiently reduced only the TC levels (−0.15 mmol/L). TG (0.00 mmol/L), LDL-C (−0.04 mmol/L) and HDL-C (−0.02 mmol/L) levels were not different between CPAP and the sham CPAP/control groups [338]. According to their subgroup analysis, younger subjects, more obese patients and patients with a longer duration of CPAP showed a significant decrease in TC concentrations (−0.27, −0.24 and −0.20 mmol/L). The authors postulated that CPAP therapy may not have any clinical effect on circulating lipid levels [338]. In the meta-analysis of Lin et al., six studies with 699 subjects met the inclusion criteria [339]. The time of the therapy was 4-24 weeks. Significant improvements in TC (−6.23 mg/dL), TG (−12.60 mg/dL) and HDL-C (−1.05 mg/dL) levels were detected but LDL-C concentrations did not decrease (−1.01 mg/dL) after CPAP therapy. Moreover, moderate-to-severe OSA, daytime sleepiness, CPAP treatment with short-term duration and good compliance were associated with the changes in lipid profile [339]. In a recent paper by Chen et al., 14 studies with 1792 subjects were included [340]. The therapy duration was 4-48 weeks. The CPAP therapy significantly decreased the TC levels (−0.09 mmol/L); however, it failed to change the levels of TG (0.07 mmol/L), LDL-C (−0.06 mmol/L) or HDL-C (−0.03 mmol/L). The authors did not find any confounders of CPAP treatment effect on lipid profile changes [340].

CPAP may improve some aspects of dyslipidaemia. For example, CPAP decreases the levels of several inflammatory molecules by mitigating hypoxia [341], reduces sympathetic activity [342], decreases the levels of cortisol [343] and improves insulin sensitivity [344]. CPAP increased the LpL concentrations after 3–6 months in patients with OSA [111,114]. The fractional clearance rate (FCR) of TG showed a 5-fold increase after 3-month CPAP therapy, but the FCR of CE was unchanged [109]. Circulating FFAs, which are the markers of increased lipolysis, were decreased after CPAP [345]. In line with this, CPAP withdrawal dynamically increased nocturnal FFA levels [346]. CPAP reduced the markers of lipid peroxidation, such as malondialdehyde levels [347], and decreased the endothelial LOX-1 expression [348]. However, it did not influence the oxLDL levels after 1 year of therapy in patients with OSA having comorbidities [170].

In summary, the previous studies investigating the effect of CPAP on lipid profiles were inconclusive. The studies were heterogeneous with different designs and sample sizes. The negative results of some studies may suggest that CPAP treatment alone does not improve lipid profiles in patients with OSA. Dyslipidaemia in OSA is strongly associated with comorbidities, such as obesity, insulin resistance and cardiovascular diseases, which also need to be addressed with pharmacological interventions. Furthermore, the differences between CPAP trials could be due to differences in diet, which was often uncontrolled in these studies. Most importantly, the effect of CPAP on triglyceride levels was more pronounced and more sustainable when it was combined with weight loss [349].

6.2. The Effect of MAD Therapy

A mandibular advancement device (MAD) is an alternative therapy option for OSA [350]. Only a few studies evaluated the impact of MAD on lipid profile in OSA. Interestingly, Recoquillon et al. detected a significant increase in TG levels after 2 months of effective MAD therapy, whilst the other investigated lipid parameters (TC, LDL-C, HDL-C) were unchanged [351]. There was no improvement in lipid profile after 12 months of MAD therapy in the study of Venema et al. [352]. Silva et al. compared the effectiveness of MAD on the metabolic profile with CPAP: CPAP was more effective in reducing TC and LDL-C levels compared to MAD therapy after 12 months [353].

6.3. The Effect of Upper Airway Surgery

The effect of upper airway surgery on the lipid profile in OSA has been poorly investigated. Li et al. investigated the postoperative lipid profile in patients with OSA who underwent uvulopalatopharyngoplasty (UPPP) or nasal surgery [354]. In patients who underwent UPPP, serum TC and HDL-C levels were significantly improved. In patients who underwent nasal surgery, these values did not change. Patients with isolated hypertriglyceridaemia showed significant improvements in serum TG and HDL-C levels [354]. Another study detected a UPPP-induced decrease in TG and TC levels after a 3-year follow-up [355].

7. Discussion of Major Findings and Further Research Directions

As outlined above, intermittent hypoxia, oxidative stress and consequential systemic inflammation may result in lipid alterations in OSA. Although most of the studies investigating these pathways were performed in vitro or in animal models, the results were also confirmed in humans. Although large population-based studies are concordant in OSA-related dyslipidaemia, they usually did not control for diet, regular exercise or lipid-lowering medications, which could contribute to bias. Clinical studies on large groups of patients are warranted to control for these factors. Furthermore, multiple mediators that are involved in dyslipidaemia (see Section 2) have not been investigated in OSA yet.

Coexistent disorders, such as obesity, insulin resistance and nonalcoholic steatohepatitis, may also lead to systemic inflammation and dyslipidaemia. This could be a reason for inconclusive results with CPAP on lipid profile. CPAP treatment alone may not be able to improve the lipid profiles in patients with OSA. Thus, parallel treatment of these comorbidities is essential to improve dyslipidaemia. Studies should also focus on which patients benefit the most from an intervention with CPAP.

As dyslipidaemia is strongly linked to OSA, patients should actively be screened for lipid abnormalities and cardiovascular complications. The detailed lipid profile of the patients with OSA should be measured at the screening visit and later under the CPAP therapy. Patients with lipid abnormalities detected during OSA management should be also referred to the appropriate specialty. Compared to single lipid components, the use of lipid components in combination with measures of abdominal obesity could better select those patients who are at higher cardiovascular risk [356].

8. Conclusions

In summary, OSA is associated with altered lipid metabolism and results in elevated circulating lipid levels. Intermittent hypoxia, oxidative stress and inflammatory mechanisms lead to altered lipid profiles in OSA. Dyslipidaemia promotes endothelial dysfunction and consequential atherosclerosis leading to increased cardiovascular morbidity and mortality. However, OSA-associated comorbidities might enhance these alterations. Further well-designed studies investigating potential causative associations between dyslipidaemia and OSA and involving CPAP treatment are warranted. The studies in the future should also take into consideration the role of OSA-related comorbidities in the pathomechanism of OSA-related dyslipidaemia. We strongly advocate measuring blood lipids in patients with OSA to estimate and ultimately reduce cardiovascular risk in clinical practice.

Acknowledgements

Andras Bikov is supported by the NIHR Manchester BRC.

References

1. Gileles-Hillel A., Kheirandish-Gozal L., Gozal D.. Biological plausibility linking sleep apnoea and metabolic dysfunction. Nat. Rev. Endocrinol.. 2016;12 290–298. doi:10.1038/nrendo.2016.22
2. Mach F., Baigent C., Catapano A.L., Koskinas K.C., Casula M., Badimon L., et al.. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: Lipid modification to reduce cardiovascular risk: The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS). Eur. Heart J.. 2019;41 111–188. doi:10.1093/eurheartj/ehz455
3. Li J., Savransky V., Nanayakkara A., Smith P.L., O’Donnell C.P., Polotsky V.Y.. Hyperlipidemia and lipid peroxidation are dependent on the severity of chronic intermittent hypoxia. J. Appl. Physiol.. 2007;102 557–563. doi:10.1152/japplphysiol.01081.2006
4. Gündüz C., Basoglu O.K., Hedner J., Zou D., Bonsignore M.R., Hein H., et al.. Obstructive sleep apnoea independently predicts lipid levels: Data from the European Sleep Apnea Database. Respirology. 2018;23 1180–1189. doi:10.1111/resp.13372
5. Pan X., Hussain M.M.. Gut triglyceride production. Biochim. Biophys. Acta.. 2012;1821 727–735. doi:10.1016/j.bbalip.2011.09.013
6. Ramasamy I.. Recent advances in physiological lipoprotein metabolism. Clin. Chem. Lab. Med.. 2014;52 1695–1727. doi:10.1515/cclm-2013-0358
7. Zilversmit D.B.. Formation and transport of chylomicrons. Fed. Proc.. 1967;26 1599–1605.
8. Redgrave T.G.. Chylomicron metabolism. Biochem. Soc. Trans.. 2004;32 79–82. doi:10.1042/bst0320079
9. Milger K., Herrmann T., Becker C., Gotthardt D., Zickwolf J., Ehehalt R., et al.. Cellular uptake of fatty acids driven by the ER-localized acyl-CoA synthetase FATP4. J. Cell Sci.. 2006;119 4678–4688. doi:10.1242/jcs.03280
10. Black D.D.. Development and physiological regulation of intestinal lipid absorption. I. Development of intestinal lipid absorption: Cellular events in chylomicron assembly and secretion. Am. J. Physiol. Gastrointest. Liver Physiol.. 2007;293 G519–G524. doi:10.1152/ajpgi.00189.2007
11. Yen C.L., Farese R.V.. MGAT2, a monoacylglycerol acyltransferase expressed in the small intestine. J. Biol. Chem.. 2003;278 18532–18537. doi:10.1074/jbc.M301633200
12. Buhman K.K., Smith S.J., Stone S.J., Repa J.J., Wong J.S., Knapp F.F., et al.. DGAT1 is not essential for intestinal triacylglycerol absorption or chylomicron synthesis. J. Biol. Chem.. 2002;277 25474–25479. doi:10.1074/jbc.M202013200
13. Ko C.W., Qu J., Black D.D., Tso P.. Regulation of intestinal lipid metabolism: Current concepts and relevance to disease. Nat. Rev. Gastroenterol. Hepatol.. 2020;17 169–183. doi:10.1038/s41575-019-0250-7
14. Hussain M.M., Kancha R.K., Zhou Z., Luchoomun J., Zu H., Bakillah A.. Chylomicron assembly and catabolism: Role of apolipoproteins and receptors. Biochim. Biophys. Acta. 1996;1300 151–170. doi:10.1016/0005-2760(96)00041-0
15. Kumar N.S., Mansbach C.M.. Prechylomicron transport vesicle: Isolation and partial characterization. Am. J. Physiol.. 1999;276 G378–G386. doi:10.1152/ajpgi.1999.276.2.G378
16. Siddiqi S., Saleem U., Abumrad N.A., Davidson N.O., Storch J., Siddiqi S.A., et al.. A novel multiprotein complex is required to generate the prechylomicron transport vesicle from intestinal ER. J. Lipid Res.. 2010;51 1918–1928. doi:10.1194/jlr.M005611
17. Siddiqi S.A., Mahan J., Siddiqi S., Gorelick F.S., Mansbach C.M.. Vesicle-associated membrane protein 7 is expressed in intestinal ER. J. Cell Sci.. 2006;119 943–950. doi:10.1242/jcs.02803
18. Havel R.J., Kane J.P., Kashyap M.L.. Interchange of apolipoproteins between chylomicrons and high density lipoproteins during alimentary lipemia in man. J. Clin. Investig.. 1973;52 32–38. doi:10.1172/JCI107171
19. Willnow T.E.. Mechanisms of hepatic chylomicron remnant clearance. Diabet. Med.. 1997;14 S75–S80. doi:10.1002/(SICI)1096-9136(199708)14:3+&lt;S75::AID-DIA449&gt;3.0.CO;2-9
20. Tiwari S., Siddiqi S.A.. Intracellular trafficking and secretion of VLDL. Arterioscler. Thromb. Vasc. Biol.. 2012;32 1079–1086. doi:10.1161/ATVBAHA.111.241471
21. Shelness G.S., Ingram M.F., Huang X.F., DeLozier J.A.. Apolipoprotein B in the rough endoplasmic reticulum: Translation, translocation and the initiation of lipoprotein assembly. J. Nutr.. 1999;129 456s–462s. doi:10.1093/jn/129.2.456S
22. Qin W., Sundaram M., Wang Y., Zhou H., Zhong S., Chang C.-C., et al.. Missense mutation in APOC3 within the C-terminal lipid binding domain of human ApoC-III results in impaired assembly and secretion of triacylglycerol-rich very low density lipoproteins: Evidence that ApoC-III plays a major role in the formation of lipid precursors within the microsomal lumen. J. Biol. Chem.. 2011;286 27769–27780. doi:10.1074/jbc.M110.203679
23. Gusarova V., Seo J., Sullivan M.L., Watkins S.C., Brodsky J.L., Fisher E.A.. Golgi-associated maturation of very low density lipoproteins involves conformational changes in apolipoprotein B, but is not dependent on apolipoprotein E. J. Biol. Chem.. 2007;282 19453–19462. doi:10.1074/jbc.M700475200
24. Soutar A.K., Myant N.B., Thompson G.R.. The metabolism of very low density and intermediate density lipoproteins in patients with familial hypercholesterolaemia. Atherosclerosis. 1982;43 217–231. doi:10.1016/0021-9150(82)90024-7
25. Takahashi S., Sakai J., Fujino T., Hattori H., Zenimaru Y., Suzuki J., et al.. The Very Low-density Lipoprotein (VLDL) Receptor: Characterization and Functions as a Peripheral Lipoprotein Receptor. J. Atheroscler. Thromb.. 2004;11 200–208. doi:10.5551/jat.11.200
26. Esterbauer H., Gebicki J., Puhl H., Jürgens G.. The role of lipid peroxidation and antioxidants in oxidative modification of LDL. Free Radic. Biol. Med.. 1992;13 341–390. doi:10.1016/0891-5849(92)90181-F
27. Shelness G.S., Sellers J.A.. Very-low-density lipoprotein assembly and secretion. Curr. Opin. Lipidol.. 2001;12 151–157. doi:10.1097/00041433-200104000-00008
28. Orekhov A.N., Tertov V.V., Mukhin D.N., Mikhailenko I.A.. Modification of low density lipoprotein by desialylation causes lipid accumulation in cultured cells: Discovery of desialylated lipoprotein with altered cellular metabolism in the blood of atherosclerotic patients. Biochem. Biophys. Res. Commun.. 1989;162 206–211. doi:10.1016/0006-291X(89)91982-7
29. Quinn M.T., Parthasarathy S., Fong L.G., Steinberg D.. Oxidatively modified low density lipoproteins: A potential role in recruitment and retention of monocyte/macrophages during atherogenesis. Proc. Natl. Acad. Sci. USA. 1987;84 2995–2998. doi:10.1073/pnas.84.9.2995
30. Sobenin I.A., Tertov V.V., Orekhov A.N.. Characterization of chemical composition of native and modified low density lipoprotein occurring in the blood of diabetic patients. Int. Angiol.. 1994;13 78–83.
31. Kollar B., Siarnik P., Hluchanova A., Klobucnikova K., Mucska I., Turcani P., et al.. The impact of sleep apnea syndrome on the altered lipid metabolism and the redox balance. Lipids Health Dis.. 2021;20 175. doi:10.1186/s12944-021-01604-8
32. Khosravi M., Hosseini-Fard R., Najafi M.. Circulating low density lipoprotein (LDL). Horm. Mol. Biol. Clin. Investig.. 2018;35 doi:10.1515/hmbci-2018-0024
33. McPherson R., Gauthier A.. Molecular regulation of SREBP function: The Insig-SCAP connection and isoform-specific modulation of lipid synthesis. Biochem. Cell Biol.. 2004;82 201–211. doi:10.1139/o03-090
34. Brown M.S., Goldstein J.L.. A proteolytic pathway that controls the cholesterol content of membranes, cells, and blood. Proc. Natl. Acad. Sci. USA. 1999;96 11041–11048. doi:10.1073/pnas.96.20.11041
35. Nohturfft A., DeBose-Boyd R.A., Scheek S., Goldstein J.L., Brown M.S.. Sterols regulate cycling of SREBP cleavage-activating protein (SCAP) between endoplasmic reticulum and Golgi. Proc. Natl. Acad. Sci. USA. 1999;96 11235–11240. doi:10.1073/pnas.96.20.11235
36. Adams C.M., Goldstein J.L., Brown M.S.. Cholesterol-induced conformational change in SCAP enhanced by Insig proteins and mimicked by cationic amphiphiles. Proc. Natl. Acad. Sci. USA. 2003;100 10647–10652. doi:10.1073/pnas.1534833100
37. Maxwell K.N., Breslow J.L.. Adenoviral-mediated expression of Pcsk9 in mice results in a low-density lipoprotein receptor knockout phenotype. Proc. Natl. Acad. Sci. USA. 2004;101 7100–7105. doi:10.1073/pnas.0402133101
38. Gorovoy M., Gaultier A., Campana W.M., Firestein G.S., Gonias S.L.. Inflammatory mediators promote production of shed LRP1/CD91, which regulates cell signaling and cytokine expression by macrophages. J. Leukoc. Biol.. 2010;88 769–778. doi:10.1189/jlb.0410220
39. Laatsch A., Merkel M., Talmud P.J., Grewal T., Beisiegel U., Heeren J.. Insulin stimulates hepatic low density lipoprotein receptor-related protein 1 (LRP1) to increase postprandial lipoprotein clearance. Atherosclerosis. 2009;204 105–111. doi:10.1016/j.atherosclerosis.2008.07.046
40. Beisiegel U., Weber W., Bengtsson-Olivecrona G.. Lipoprotein lipase enhances the binding of chylomicrons to low density lipoprotein receptor-related protein. Proc. Natl. Acad. Sci. USA. 1991;88 8342–8346. doi:10.1073/pnas.88.19.8342
41. Kounnas M.Z., Chappell D.A., Wong H., Argraves W.S., Strickland D.K.. The Cellular Internalization and Degradation of Hepatic Lipase Is Mediated by Low Density Lipoprotein Receptor-related Protein and Requires Cell Surface Proteoglycans. J. Biol. Chem.. 1995;270 9307–9312. doi:10.1074/jbc.270.16.9307
42. Laatsch A., Panteli M., Sornsakrin M., Hoffzimmer B., Grewal T., Heeren J.. Low density lipoprotein receptor-related protein 1 dependent endosomal trapping and recycling of apolipoprotein E. PLoS ONE. 2012;7 doi:10.1371/journal.pone.0029385
43. Lillis A.P., Muratoglu S.C., Au D.T., Migliorini M., Lee M.J., Fried S.K., et al.. LDL receptor-related protein-1 (LRP1) regulates cholesterol accumulation in macrophages. PLoS ONE. 2015;10 doi:10.1371/journal.pone.0128903
44. Samouillan V., Dandurand J., Nasarre L., Badimon L., Lacabanne C., Llorente-Cortés V.. Lipid loading of human vascular smooth muscle cells induces changes in tropoelastin protein levels and physical structure. Biophys. J.. 2012;103 532–540. doi:10.1016/j.bpj.2012.06.034
45. Ranganathan S., Cao C., Catania J., Migliorini M., Zhang L., Strickland D.K.. Molecular basis for the interaction of low density lipoprotein receptor-related protein 1 (LRP1) with integrin alphaMbeta2: Identification of binding sites within alphaMbeta2 for LRP1. J. Biol. Chem.. 2011;286 30535–30541. doi:10.1074/jbc.M111.265413
46. Gaultier A., Arandjelovic S., Li X., Janes J., Dragojlovic N., Zhou G.P., et al.. A shed form of LDL receptor-related protein-1 regulates peripheral nerve injury and neuropathic pain in rodents. J. Clin. Investig.. 2008;118 161–172. doi:10.1172/JCI32371
47. Beigneux A.P., Davies B.S.J., Gin P., Weinstein M.M., Farber E., Qiao X., et al.. Glycosylphosphatidylinositol-Anchored High-Density Lipoprotein-Binding Protein 1 Plays a Critical Role in the Lipolytic Processing of Chylomicrons. Cell Metab.. 2007;5 279–291. doi:10.1016/j.cmet.2007.02.002
48. Kersten S.. Physiological regulation of lipoprotein lipase. Biochim. Biophys. Acta (BBA)-Mol. Cell Biol. Lipids. 2014;1841 919–933. doi:10.1016/j.bbalip.2014.03.013
49. Doolittle M.H., Ben-Zeev O., Elovson J., Martin D., Kirchgessner T.G.. The response of lipoprotein lipase to feeding and fasting. Evidence for posttranslational regulation. J. Biol. Chem.. 1990;265 4570–4577. doi:10.1016/S0021-9258(19)39601-2
50. Borensztajn J., Robinson D.S.T.. The effect of fasting on the utilization of chylomicron triglyceride fatty acids in relation to clearing factor lipase (lipoprotein lipase) releasable by heparin in the perfused rat heart. J. Lipid Res.. 1970;11 111–117. doi:10.1016/S0022-2275(20)43001-9
51. Hamilton M.T., Etienne J., McClure W.C., Pavey B.S., Holloway A.K.. Role of local contractile activity and muscle fiber type on LPL regulation during exercise. Am. J. Physiol.. 1998;275 E1016–E1022. doi:10.1152/ajpendo.1998.275.6.E1016
52. Larsson M., Vorrsjö E., Talmud P., Lookene A., Olivecrona G.. Apolipoproteins C-I and C-III Inhibit Lipoprotein Lipase Activity by Displacement of the Enzyme from Lipid Droplets*. J. Biol. Chem.. 2013;288 33997–34008. doi:10.1074/jbc.M113.495366
53. Quagliarini F., Wang Y., Kozlitina J., Grishin N.V., Hyde R., Boerwinkle E., et al.. Atypical angiopoietin-like protein that regulates ANGPTL3. Proc. Natl. Acad. Sci. USA. 2012;109 19751. doi:10.1073/pnas.1217552109
54. Mandard S., Zandbergen F., van Straten E., Wahli W., Kuipers F., Müller M., et al.. The Fasting-induced Adipose Factor/Angiopoietin-like Protein 4 Is Physically Associated with Lipoproteins and Governs Plasma Lipid Levels and Adiposity. J. Biol. Chem.. 2006;281 934–944. doi:10.1074/jbc.M506519200
55. Tosheska Trajkovska K., Topuzovska S.. High-density lipoprotein metabolism and reverse cholesterol transport: Strategies for raising HDL cholesterol. Anatol. J. Cardiol.. 2017;18 149–154. doi:10.14744/AnatolJCardiol.2017.7608
56. Rached F.H., Chapman M.J., Kontush A.. HDL particle subpopulations: Focus on biological function. Biofactors. 2015;41 67–77. doi:10.1002/biof.1202
57. von Eckardstein A., Kardassis D.. High Density Lipoproteins: From Biological Understanding to Clinical Exploitation. 2015 694.
58. Camont L., Chapman M.J., Kontush A.. Biological activities of HDL subpopulations and their relevance to cardiovascular disease. Trends. Mol. Med.. 2011;17 594–603. doi:10.1016/j.molmed.2011.05.013
59. Oravec S., Dukat A., Gavornik P., Caprnda M., Kucera M., Ocadlik I.. Contribution of the atherogenic lipoprotein profile to the development of arterial hypertension. Bratisl Lek Listy. 2011;112 4–7.
60. Oravec S., Dostal E., Dukát A., Gavorník P., Kucera M., Gruber K.. HDL subfractions analysis: A new laboratory diagnostic assay for patients with cardiovascular diseases and dyslipoproteinemia. Neuro. Endocrinol. Lett.. 2011;32 502–509.
61. Tailleux A., Duriez P., Fruchart J.C., Clavey V.. Apolipoprotein A-II, HDL metabolism and atherosclerosis. Atherosclerosis. 2002;164 1–13. doi:10.1016/S0021-9150(01)00751-1
62. Klimov A.N., Gurevich V.S., Nikiforova A.A., Shatilina L.V., Kuzmin A.A., Plavinsky S.L., et al.. Antioxidative activity of high density lipoproteins in vivo. Atherosclerosis. 1993;100 13–18. doi:10.1016/0021-9150(93)90063-Z
63. Frank P.G., Marcel Y.L.. Apolipoprotein A-I: Structure-function relationships. J. Lipid Res.. 2000;41 853–872. doi:10.1016/S0022-2275(20)32028-9
64. Dominiczak M.H., Caslake M.J.. Apolipoproteins: Metabolic role and clinical biochemistry applications. Ann. Clin. Biochem.. 2011;48 498–515. doi:10.1258/acb.2011.011111
65. Mulya A., Seo J., Brown A.L., Gebre A.K., Boudyguina E., Shelness G.S., et al.. Apolipoprotein M expression increases the size of nascent pre beta HDL formed by ATP binding cassette transporter A1. J. Lipid Res.. 2010;51 514–524. doi:10.1194/jlr.M002162
66. Christoffersen C., Nielsen L.B., Axler O., Andersson A., Johnsen A.H., Dahlbäck B.. Isolation and characterization of human apolipoprotein M-containing lipoproteins. J. Lipid Res.. 2006;47 1833–1843. doi:10.1194/jlr.M600055-JLR200
67. Christoffersen C., Obinata H., Kumaraswamy S.B., Galvani S., Ahnström J., Sevvana M., et al.. Endothelium-protective sphingosine-1-phosphate provided by HDL-associated apolipoprotein M. Proc. Natl. Acad. Sci. USA. 2011;108 9613–9618. doi:10.1073/pnas.1103187108
68. van der Vorst E.P.C.. High-Density Lipoproteins and Apolipoprotein A1. Subcell Biochem.. 2020;94 399–420. doi:10.1007/978-3-030-41769-7_16
69. Pereira R.M., Mekary R.A., da Cruz Rodrigues K.C., Anaruma C.P., Ropelle E.R., da Silva A.S.R., et al.. Protective molecular mechanisms of clusterin against apoptosis in cardiomyocytes. Heart Fail. Rev.. 2018;23 123–129. doi:10.1007/s10741-017-9654-z
70. Timmins J.M., Lee J.-Y., Boudyguina E., Kluckman K.D., Brunham L.R., Mulya A., et al.. Targeted inactivation of hepatic Abca1 causes profound hypoalphalipoproteinemia and kidney hypercatabolism of apoA-I. J. Clin. Investig.. 2005;115 1333–1342. doi:10.1172/JCI200523915
71. Brunham L.R., Kruit J.K., Iqbal J., Fievet C., Timmins J.M., Pape T.D., et al.. Intestinal ABCA1 directly contributes to HDL biogenesis in vivo. J. Clin. Investig.. 2006;116 1052–1062. doi:10.1172/JCI27352
72. Langmann T., Klucken J., Reil M., Liebisch G., Luciani M.F., Chimini G., et al.. Molecular cloning of the human ATP-binding cassette transporter 1 (hABC1): Evidence for sterol-dependent regulation in macrophages. Biochem. Biophys. Res. Commun.. 1999;257 29–33. doi:10.1006/bbrc.1999.0406
73. Oram J.F., Vaughan A.M.. ABCA1-mediated transport of cellular cholesterol and phospholipids to HDL apolipoproteins. Curr. Opin. Lipidol.. 2000;11 253–260. doi:10.1097/00041433-200006000-00005
74. Bailey D., Ruel I., Hafiane A., Cochrane H., Iatan I., Jauhiainen M., et al.. Analysis of lipid transfer activity between model nascent HDL particles and plasma lipoproteins: Implications for current concepts of nascent HDL maturation and genesis. J. Lipid Res.. 2010;51 785–797. doi:10.1194/jlr.M001875
75. Jauhiainen M., Metso J., Pahlman R., Blomqvist S., van Tol A., Ehnholm C.. Human plasma phospholipid transfer protein causes high density lipoprotein conversion. J. Biol. Chem.. 1993;268 4032–4036. doi:10.1016/S0021-9258(18)53575-4
76. Acton S., Rigotti A., Landschulz K.T., Xu S., Hobbs H.H., Krieger M.. Identification of scavenger receptor SR-BI as a high density lipoprotein receptor. Science. 1996;271 518–520. doi:10.1126/science.271.5248.518
77. Xu S., Laccotripe M., Huang X., Rigotti A., Zannis V.I., Krieger M.. Apolipoproteins of HDL can directly mediate binding to the scavenger receptor SR-BI, an HDL receptor that mediates selective lipid uptake. J. Lipid Res.. 1997;38 1289–1298. doi:10.1016/S0022-2275(20)37413-7
78. Thuren T.. Hepatic lipase and HDL metabolism. Curr. Opin. Lipidol.. 2000;11 277–283. doi:10.1097/00041433-200006000-00008
79. Chapman M.J., Le Goff W., Guerin M., Kontush A.. Cholesteryl ester transfer protein: At the heart of the action of lipid-modulating therapy with statins, fibrates, niacin, and cholesteryl ester transfer protein inhibitors. Eur. Heart J.. 2010;31 149–164. doi:10.1093/eurheartj/ehp399
80. Barter P.J., Brewer H.B., Chapman M.J., Hennekens C.H., Rader D.J., Tall A.R.. Cholesteryl ester transfer protein: A novel target for raising HDL and inhibiting atherosclerosis. Arterioscler. Thromb. Vasc. Biol.. 2003;23 160–167. doi:10.1161/01.ATV.0000054658.91146.64
81. Silver D.L., Wang N., Xiao X., Tall A.R.. High density lipoprotein (HDL) particle uptake mediated by scavenger receptor class B type 1 results in selective sorting of HDL cholesterol from protein and polarized cholesterol secretion. J. Biol. Chem.. 2001;276 25287–25293. doi:10.1074/jbc.M101726200
82. Pagler T.A., Rhode S., Neuhofer A., Laggner H., Strobl W., Hinterndorfer C., et al.. SR-BI-mediated high density lipoprotein (HDL) endocytosis leads to HDL resecretion facilitating cholesterol efflux. J. Biol. Chem.. 2006;281 11193–11204. doi:10.1074/jbc.M510261200
83. Daniil G., Phedonos A.A., Holleboom A.G., Motazacker M.M., Argyri L., Kuivenhoven J.A., et al.. Characterization of antioxidant/anti-inflammatory properties and apoA-I-containing subpopulations of HDL from family subjects with monogenic low HDL disorders. Clin. Chim. Acta.. 2011;412 1213–1220. doi:10.1016/j.cca.2011.03.011
84. Kontush A., Chantepie S., Chapman M.J.. Small, dense HDL particles exert potent protection of atherogenic LDL against oxidative stress. Arterioscler. Thromb. Vasc. Biol.. 2003;23 1881–1888. doi:10.1161/01.ATV.0000091338.93223.E8
85. Shuhei N., Söderlund S., Jauhiainen M., Taskinen M.R.. Effect of HDL composition and particle size on the resistance of HDL to the oxidation. Lipids Health Dis.. 2010;9 104. doi:10.1186/1476-511X-9-104
86. Aviram M., Rosenblat M., Bisgaier C.L., Newton R.S., Primo-Parmo S.L., La Du B.N.. Paraoxonase inhibits high-density lipoprotein oxidation and preserves its functions. A possible peroxidative role for paraoxonase. J. Clin. Investig.. 1998;101 1581–1590. doi:10.1172/JCI1649
87. Nicholls S.J., Dusting G.J., Cutri B., Bao S., Drummond G.R., Rye K.A., et al.. Reconstituted high-density lipoproteins inhibit the acute pro-oxidant and proinflammatory vascular changes induced by a periarterial collar in normocholesterolemic rabbits. Circulation. 2005;111 1543–1550. doi:10.1161/01.CIR.0000159351.95399.50
88. Yvan-Charvet L., Wang N., Tall A.R.. Role of HDL, ABCA1, and ABCG1 Transporters in Cholesterol Efflux and Immune Responses. Arterioscler. Thromb. Vasc. Biol.. 2010;30 139–143. doi:10.1161/ATVBAHA.108.179283
89. Almendros I., Basoglu Ö.K., Conde S.V., Liguori C., Saaresranta T.. Metabolic dysfunction in OSA: Is there something new under the sun?. J. Sleep Res.. 2022;31 e13418. doi:10.1111/jsr.13418
90. Farré R., Montserrat J.M., Gozal D., Almendros I., Navajas D.. Intermittent Hypoxia Severity in Animal Models of Sleep Apnea. Front. Physiol.. 2018;9 1556. doi:10.3389/fphys.2018.01556
91. Li J., Thorne L.N., Punjabi N.M., Sun C.K., Schwartz A.R., Smith P.L., et al.. Intermittent hypoxia induces hyperlipidemia in lean mice. Circ. Res.. 2005;97 698–706. doi:10.1161/01.RES.0000183879.60089.a9
92. Li J., Bosch-Marce M., Nanayakkara A., Savransky V., Fried S.K., Semenza G.L., et al.. Altered metabolic responses to intermittent hypoxia in mice with partial deficiency of hypoxia-inducible factor-1alpha. Physiol. Genom.. 2006;25 450–457. doi:10.1152/physiolgenomics.00293.2005
93. Tabor D.E., Kim J.B., Spiegelman B.M., Edwards P.A.. Identification of conserved cis-elements and transcription factors required for sterol-regulated transcription of stearoyl-CoA desaturase 1 and 2. J. Biol. Chem.. 1999;274 20603–20610. doi:10.1074/jbc.274.29.20603
94. Savransky V., Nanayakkara A., Li J., Bevans S., Smith P.L., Rodriguez A., et al.. Chronic intermittent hypoxia induces atherosclerosis. Am. J. Respir. Crit. Care Med.. 2007;175 1290–1297. doi:10.1164/rccm.200612-1771OC
95. Tamisier R., Gilmartin G.S., Launois S.H., Pépin J.L., Nespoulet H., Thomas R., et al.. A new model of chronic intermittent hypoxia in humans: Effect on ventilation, sleep, and blood pressure. J. Appl. Physiol.. 2009;107 17–24. doi:10.1152/japplphysiol.91165.2008
96. Dobrosielski D.A., Papandreou C., Patil S.P., Salas-Salvadó J.. Diet and exercise in the management of obstructive sleep apnoea and cardiovascular disease risk. Eur. Respir. Rev.. 2017;26 doi:10.1183/16000617.0110-2016
97. Giel K.E., Bulik C.M., Fernandez-Aranda F., Hay P., Keski-Rahkonen A., Schag K., et al.. Binge eating disorder. Nat. Rev. Dis. Primers. 2022;8 16. doi:10.1038/s41572-022-00344-y
98. Matsumoto T., Harada N., Azuma M., Chihara Y., Murase K., Tachikawa R., et al.. Plasma Incretin Levels and Dipeptidyl Peptidase-4 Activity in Patients with Obstructive Sleep Apnea. Ann. Am. Thorac. Soc.. 2016;13 1378–1387. doi:10.1513/AnnalsATS.201510-697OC
99. Shobatake R., Itaya-Hironaka A., Yamauchi A., Makino M., Sakuramoto-Tsuchida S., Uchiyama T., et al.. Intermittent Hypoxia Up-Regulates Gene Expressions of Peptide YY (PYY), Glucagon-like Peptide-1 (GLP-1), and Neurotensin (NTS) in Enteroendocrine Cells. Int. J. Mol. Sci.. 2019;20 doi:10.3390/ijms20081849
100. Hakim F., Wang Y., Carreras A., Hirotsu C., Zhang J., Peris E., et al.. Chronic sleep fragmentation during the sleep period induces hypothalamic endoplasmic reticulum stress and PTP1b-mediated leptin resistance in male mice. Sleep. 2015;38 31–40. doi:10.5665/sleep.4320
101. Dash S., Xiao C., Morgantini C., Lewis G.F.. New Insights into the Regulation of Chylomicron Production. Annu. Rev. Nutr.. 2015;35 265–294. doi:10.1146/annurev-nutr-071714-034338
102. Phillips C.L., Yee B.J., Marshall N.S., Liu P.Y., Sullivan D.R., Grunstein R.R.. Continuous positive airway pressure reduces postprandial lipidemia in obstructive sleep apnea: A randomized, placebo-controlled crossover trial. Am. J. Respir. Crit. Care Med.. 2011;184 355–361. doi:10.1164/rccm.201102-0316OC
103. Drager L.F., Li J., Shin M.K., Reinke C., Aggarwal N.R., Jun J.C., et al.. Intermittent hypoxia inhibits clearance of triglyceride-rich lipoproteins and inactivates adipose lipoprotein lipase in a mouse model of sleep apnoea. Eur. Heart J.. 2012;33 783–790. doi:10.1093/eurheartj/ehr097
104. Morin R., Mauger J.F., Amaratunga R., Imbeault P.. The effect of acute intermittent hypoxia on postprandial triglyceride levels in humans: A randomized crossover trial. J. Transl. Med.. 2021;19 268. doi:10.1186/s12967-021-02933-z
105. Mwaikambo B.R., Yang C., Chemtob S., Hardy P.. Hypoxia up-regulates CD36 expression and function via hypoxia-inducible factor-1- and phosphatidylinosi.itol 3-kinase-dependent mechanisms. J. Biol. Chem.. 2009;284 26695–26707. doi:10.1074/jbc.M109.033480
106. Flores J.J., Klebe D., Rolland W.B., Lekic T., Krafft P.R., Zhang J.H.. PPARγ-induced upregulation of CD36 enhances hematoma resolution and attenuates long-term neurological deficits after germinal matrix hemorrhage in neonatal rats. Neurobiol. Dis.. 2016;87 124–133. doi:10.1016/j.nbd.2015.12.015
107. Rey E., Del Pozo-Maroto E., Marañón P., Beeler B., García-García Y., Landete P., et al.. Intrahepatic Expression of Fatty Acid Translocase CD36 Is Increased in Obstructive Sleep Apnea. Front. Med.. 2020;7 450. doi:10.3389/fmed.2020.00450
108. Moon Y., Park B., Park H.. Hypoxic repression of CYP7A1 through a HIF-1α- and SHP-independent mechanism. BMB Rep.. 2016;49 173–178. doi:10.5483/BMBRep.2016.49.3.188
109. Drager L.F., Tavoni T.M., Silva V.M., Santos R.D., Pedrosa R.P., Bortolotto L.A., et al.. Obstructive sleep apnea and effects of continuous positive airway pressure on triglyceride-rich lipoprotein metabolism. J. Lipid Res.. 2018;59 1027–1033. doi:10.1194/jlr.M083436
110. Mahat B., Chassé É., Mauger J.-F., Imbeault P.. Effects of acute hypoxia on human adipose tissue lipoprotein lipase activity and lipolysis. J. Transl. Med.. 2016;14 212. doi:10.1186/s12967-016-0965-y
111. Iesato K., Tatsumi K., Saibara T., Nakamura A., Terada J., Tada Y., et al.. Decreased lipoprotein lipase in obstructive sleep apnea syndrome. Circ. J.. 2007;71 1293–1298. doi:10.1253/circj.71.1293
112. Yao Q., Shin M.K., Jun J.C., Hernandez K.L., Aggarwal N.R., Mock J.R., et al.. Effect of chronic intermittent hypoxia on triglyceride uptake in different tissues. J. Lipid Res.. 2013;54 1058–1065. doi:10.1194/jlr.M034272
113. Jun J.C., Shin M.K., Yao Q., Bevans-Fonti S., Poole J., Drager L.F., et al.. Acute hypoxia induces hypertriglyceridemia by decreasing plasma triglyceride clearance in mice. Am. J. Physiol. Endocrinol. Metab.. 2012;303 E377–E388. doi:10.1152/ajpendo.00641.2011
114. Li J., Zhang Y., Wang J., Feng P., Chen R., Cao Y., et al.. Association between serum lipoprotein lipase level and dyslipidemia in patients with obstructive sleep apnea syndrome. Zhonghua Yi Xue Za Zhi. 2014;94 403–407.
115. Drager L.F., Yao Q., Hernandez K.L., Shin M.K., Bevans-Fonti S., Gay J., et al.. Chronic intermittent hypoxia induces atherosclerosis via activation of adipose angiopoietin-like 4. Am. J. Respir. Crit. Care Med.. 2013;188 240–248. doi:10.1164/rccm.201209-1688OC
116. Al-Terki A., Abu-Farha M., AlKhairi I., Cherian P.T., Sriraman D., Shyamsundar A., et al.. Increased Level of Angiopoietin Like Proteins 4 and 8 in People With Sleep Apnea. Front. Endocrinol.. 2018;9 doi:10.3389/fendo.2018.00651
117. Li J., Yang Y., Jiao X., Yu H., Du Y., Zhang M., et al.. The Clinical Role of Angiopoietin-Like Protein 3 in Evaluating Coronary Artery Disease in Patients with Obstructive Sleep Apnea. Cardiovasc. Drugs. 2020;34 773–780. doi:10.1007/s10557-020-06991-1
118. Schoonjans K., Peinado-Onsurbe J., Lefebvre A.M., Heyman R.A., Briggs M., Deeb S., et al.. PPARalpha and PPARgamma activators direct a distinct tissue-specific transcriptional response via a PPRE in the lipoprotein lipase gene. Embo J.. 1996;15 5336–5348. doi:10.1002/j.1460-2075.1996.tb00918.x
119. Yun Z., Maecker H.L., Johnson R.S., Giaccia A.J.. Inhibition of PPAR gamma 2 gene expression by the HIF-1-regulated gene DEC1/Stra13: A mechanism for regulation of adipogenesis by hypoxia. Dev. Cell. 2002;2 331–341. doi:10.1016/S1534-5807(02)00131-4
120. Mackay A.G., Oliver J.D., Rogers M.P.. Regulation of lipoprotein lipase activity and mRNA content in rat epididymal adipose tissue in vitro by recombinant tumour necrosis factor. Biochem. J.. 1990;269 123–126. doi:10.1042/bj2690123
121. Feingold K.R., Marshall M., Gulli R., Moser A.H., Grunfeld C.. Effect of endotoxin and cytokines on lipoprotein lipase activity in mice. Arterioscler. Thromb.. 1994;14 1866–1872. doi:10.1161/01.ATV.14.11.1866
122. Grunfeld C., Gulli R., Moser A.H., Gavin L.A., Feingold K.R.. Effect of tumor necrosis factor administration in vivo on lipoprotein lipase activity in various tissues of the rat. J. Lipid Res.. 1989;30 579–585. doi:10.1016/S0022-2275(20)38349-8
123. Zechner R., Newman T.C., Sherry B., Cerami A., Breslow J.L.. Recombinant human cachectin/tumor necrosis factor but not interleukin-1 alpha downregulates lipoprotein lipase gene expression at the transcriptional level in mouse 3T3-L1 adipocytes. Mol. Cell. Biol.. 1988;8 2394. doi:10.1128/mcb.8.6.2394-2401.1988
124. Wu G., Brouckaert P., Olivecrona T.. Rapid downregulation of adipose tissue lipoprotein lipase activity on food deprivation: Evidence that TNF-alpha is involved. Am. J. Physiol. Endocrinol. Metab.. 2004;286 E711–E717. doi:10.1152/ajpendo.00257.2003
125. Somers V.K., Dyken M.E., Clary M.P., Abboud F.M.. Sympathetic neural mechanisms in obstructive sleep apnea. J. Clin. Investig.. 1995;96 1897–1904. doi:10.1172/JCI118235
126. Raynolds M.V., Awald P.D., Gordon D.F., Gutierrez-Hartmann A., Rule D.C., Wood W.M., et al.. Lipoprotein Lipase Gene Expression in Rat Adipocytes Is Regulated by Isoproterenol and Insulin through Different Mechanisms. Mol. Endocrinol.. 1990;4 1416–1422. doi:10.1210/mend-4-9-1416
127. Chiappe de Cingalani G.E., Goers J.W., Giannotti M., Caldiz C.I.. Comparative effects of insulin and isoproterenol on lipoprotein lipase in rat adipose cells. Am. J. Physiol.-Cell Physiol.. 1996;270 C1461–C1467. doi:10.1152/ajpcell.1996.270.5.C1461
128. Dijk W., Heine M., Vergnes L., Boon M.R., Schaart G., Hesselink M.K., et al.. ANGPTL4 mediates shuttling of lipid fuel to brown adipose tissue during sustained cold exposure. Elife. 2015;4 doi:10.7554/eLife.08428
129. Ong J.M., Kirchgessner T.G., Schotz M.C., Kern P.A.. Insulin increases the synthetic rate and messenger RNA level of lipoprotein lipase in isolated rat adipocytes. J. Biol. Chem.. 1988;263 12933–12938. doi:10.1016/S0021-9258(18)37651-8
130. Inukai K., Nakashima Y., Watanabe M., Kurihara S., Awata T., Katagiri H., et al.. ANGPTL3 is increased in both insulin-deficient and -resistant diabetic states. Biochem. Biophys. Res. Commun.. 2004;317 1075–1079. doi:10.1016/j.bbrc.2004.03.151
131. Picard F., Richard D., Huang Q., Deshaies Y.. Effects of leptin adipose tissue lipoprotein lipase in the obese ob/ob mouse. Int. J. Obes.. 1998;22 1088–1095. doi:10.1038/sj.ijo.0800732
132. Shimamura M., Matsuda M., Ando Y., Koishi R., Yasumo H., Furukawa H., et al.. Leptin and insulin down-regulate angiopoietin-like protein 3, a plasma triglyceride-increasing factor. Biochem. Biophys. Res. Commun.. 2004;322 1080–1085. doi:10.1016/j.bbrc.2004.08.024
133. Phillips B.G., Kato M., Narkiewicz K., Choe I., Somers V.K.. Increases in leptin levels, sympathetic drive, and weight gain in obstructive sleep apnea. Am. J. Physiol. Heart Circ. Physiol.. 2000;279 H234–H237. doi:10.1152/ajpheart.2000.279.1.H234
134. Zeng F., Wang X., Hu W., Wang L.. Association of adiponectin level and obstructive sleep apnea prevalence in obese subjects. Medicine. 2017;96 e7784. doi:10.1097/MD.0000000000007784
135. von Eynatten M., Schneider J.G., Humpert P.M., Rudofsky G., Schmidt N., Barosch P., et al.. Decreased plasma lipoprotein lipase in hypoadiponectinemia: An association independent of systemic inflammation and insulin resistance. Diabetes Care. 2004;27 2925–2929. doi:10.2337/diacare.27.12.2925
136. Costales P., Castellano J., Revuelta-López E., Cal R., Aledo R., Llampayas O., et al.. Lipopolysaccharide downregulates CD91/low-density lipoprotein receptor-related protein 1 expression through SREBP-1 overexpression in human macrophages. Atherosclerosis. 2013;227 79–88. doi:10.1016/j.atherosclerosis.2012.12.021
137. Qin S., Yin J., Huang K.. Free Fatty Acids Increase Intracellular Lipid Accumulation and Oxidative Stress by Modulating PPARα and SREBP-1c in L-02 Cells. Lipids. 2016;51 797–805. doi:10.1007/s11745-016-4160-y
138. Li J., Nanayakkara A., Jun J., Savransky V., Polotsky V.Y.. Effect of deficiency in SREBP cleavage-activating protein on lipid metabolism during intermittent hypoxia. Physiol. Genom.. 2007;31 273–280. doi:10.1152/physiolgenomics.00082.2007
139. Guo Y.X., He L.Y., Zhang M., Wang F., Liu F., Peng W.X.. 1,25-Dihydroxyvitamin D3 regulates expression of LRP1 and RAGE in vitro and in vivo, enhancing Aβ1–40 brain-to-blood efflux and peripheral uptake transport. Neuroscience. 2016;322 28–38. doi:10.1016/j.neuroscience.2016.01.041
140. Zhao Y., Zeng C.Y., Li X.H., Yang T.T., Kuang X., Du J.R.. Klotho overexpression improves amyloid-β clearance and cognition in the APP/PS1 mouse model of Alzheimer’s disease. Aging Cell. 2020;19 e13239. doi:10.1111/acel.13239
141. Bozkurt N.C., Cakal E., Sahin M., Ozkaya E.C., Firat H., Delibasi T.. The relation of serum 25-hydroxyvitamin-D levels with severity of obstructive sleep apnea and glucose metabolism abnormalities. Endocrine. 2012;41 518–525. doi:10.1007/s12020-012-9595-1
142. Pákó J., Kunos L., Mészáros M., Tárnoki D.L., Tárnoki Á D., Horváth I., et al.. Decreased Levels of Anti-Aging Klotho in Obstructive Sleep Apnea. Rejuvenation Res.. 2020;23 256–261. doi:10.1089/rej.2019.2183
143. de Gonzalo-Calvo D., Cenarro A., Martínez-Bujidos M., Badimon L., Bayes-Genis A., Ordonez-Llanos J., et al.. Circulating soluble low-density lipoprotein receptor-related protein 1 (sLRP1) concentration is associated with hypercholesterolemia: A new potential biomarker for atherosclerosis. Int. J. Cardiol.. 2015;201 20–29. doi:10.1016/j.ijcard.2015.07.085
144. Meszaros M., Kunos L., Tarnoki A.D., Tarnoki D.L., Lazar Z., Bikov A.. The Role of Soluble Low-Density Lipoprotein Receptor-Related Protein-1 in Obstructive Sleep Apnoea. J. Clin. Med.. 2021;10 doi:10.3390/jcm10071494
145. Ntambi J.M., Miyazaki M.. Regulation of stearoyl-CoA desaturases and role in metabolism. Prog. Lipid Res.. 2004;43 91–104. doi:10.1016/S0163-7827(03)00039-0
146. Savransky V., Jun J., Li J., Nanayakkara A., Fonti S., Moser A.B., et al.. Dyslipidemia and atheroscleros.sis induced by chronic intermittent hypoxia are attenuated by deficiency of stearoyl coenzyme A desaturase. Circ. Res.. 2008;103 1173–1180. doi:10.1161/CIRCRESAHA.108.178533
147. Li J., Grigoryev D.N., Ye S.Q., Thorne L., Schwartz A.R., Smith P.L., et al.. Chronic intermittent hypoxia upregulates genes of lipid biosynthesis in obese mice. J. Appl. Physiol.. 2005;99 1643–1648. doi:10.1152/japplphysiol.00522.2005
148. Salceda S., Caro J.. Hypoxia-inducible factor 1alpha (HIF-1alpha) protein is rapidly degraded by the ubiquitin-proteasome system under normoxic conditions. Its stabilization by hypoxia depends on redox-induced changes. J. Biol. Chem.. 1997;272 22642–22647. doi:10.1074/jbc.272.36.22642
149. Jaakkola P., Mole D.R., Tian Y.M., Wilson M.I., Gielbert J., Gaskell S.J., et al.. Targeting of HIF-alpha to the von Hippel-Lindau ubiquitylation complex by O2-regulated prolyl hydroxylation. Science. 2001;292 468–472. doi:10.1126/science.1059796
150. Goyal P., Weissmann N., Grimminger F., Hegel C., Bader L., Rose F., et al.. Upregulation of NAD(P)H oxidase 1 in hypoxia activates hypoxia-inducible factor 1 via increase in reactive oxygen species. Free Radic. Biol. Med.. 2004;36 1279–1288. doi:10.1016/j.freeradbiomed.2004.02.071
151. Mesarwi O.A., Loomba R., Malhotra A.. Obstructive Sleep Apnea, Hypoxia, and Nonalcoholic Fatty Liver Disease. Am. J. Respir. Crit. Care Med.. 2019;199 830–841. doi:10.1164/rccm.201806-1109TR
152. Bruinstroop E., Pei L., Ackermans M.T., Foppen E., Borgers A.J., Kwakkel J., et al.. Hypothalamic neuropeptide Y (NPY) controls hepatic VLDL-triglyceride secretion in rats via the sympathetic nervous system. Diabetes. 2012;61 1043–1050. doi:10.2337/db11-1142
153. Jermendy G., Horváth T., Littvay L., Steinbach R., Jermendy A.L., Tárnoki A.D., et al.. Effect of genetic and environmental influences on cardiometabolic risk factors: A twin study. Cardiovasc. Diabetol.. 2011;10 96. doi:10.1186/1475-2840-10-96
154. Guilleminault C., Partinen M., Hollman K., Powell N., Stoohs R.. Familial aggregates in obstructive sleep apnea syndrome. Chest. 1995;107 1545–1551. doi:10.1378/chest.107.6.1545
155. Meszaros M., Tarnoki A.D., Tarnoki D.L., Kovacs D.T., Forgo B., Lee J., et al.. Obstructive sleep apnea and hypertriglyceridaemia share common genetic background: Results of a twin study. J. Sleep Res.. 2020;29 e12979. doi:10.1111/jsr.12979
156. Tang H., Zhou Q., Zheng F., Wu T., Tang Y.D., Jiang J.. The Causal Effects of Lipid Profiles on Sleep Apnea. Front. Nutr.. 2022;9 910690. doi:10.3389/fnut.2022.910690
157. Sun J., Hu J., Tu C., Zhong A., Xu H.. Obstructive sleep apnea susceptibility genes in Chinese population: A field synopsis and meta-analysis of genetic association studies. PLoS ONE. 2015;10 doi:10.1371/journal.pone.0135942
158. Li Q., Chen R., Bie L., Zhao D., Huang C., Hong J.. Association of the variants in the PPARG gene and serum lipid levels: A meta-analysis of 74 studies. J. Cell Mol. Med.. 2015;19 198–209. doi:10.1111/jcmm.12417
159. Uyrum E., Balbay O., Annakkaya A.N., Gulec Balbay E., Silan F., Arbak P.. The relationship between obstructive sleep apnea syndrome and apolipoprotein E genetic variants. Respiration. 2015;89 195–200. doi:10.1159/000369560
160. Fisher E.A., Pan M., Chen X., Wu X., Wang H., Jamil H., et al.. The triple threat to nascent apolipoprotein B. Evidence for multiple, distinct degradative pathways. J. Biol. Chem.. 2001;276 27855–27863. doi:10.1074/jbc.M008885200
161. Wen Y., Leake D.S.. Low Density Lipoprotein Undergoes Oxidation Within Lysosomes in Cells. Circ. Res.. 2007;100 1337–1343. doi:10.1161/CIRCRESAHA.107.151704
162. Itabe H., Obama T., Kato R.. The Dynamics of Oxidized LDL during Atherogenesis. J. Lipids. 2011;2011 418313. doi:10.1155/2011/418313
163. Poznyak A.V., Nikiforov N.G., Markin A.M., Kashirskikh D.A., Myasoedova V.A., Gerasimova E.V., et al.. Overview of OxLDL and Its Impact on Cardiovascular Health: Focus on Atherosclerosis. Front. Pharm.. 2020;11 613780. doi:10.3389/fphar.2020.613780
164. Younis N.N., Soran H., Pemberton P., Charlton-Menys V., Elseweidy M.M., Durrington P.N.. Small dense LDL is more susceptible to glycation than more buoyant LDL in Type 2 diabetes. Clin. Sci.. 2013;124 343–349. doi:10.1042/CS20120304
165. Ivanova E.A., Myasoedova V.A., Melnichenko A.A., Grechko A.V., Orekhov A.N.. Small Dense Low-Density Lipoprotein as Biomarker for Atherosclerotic Diseases. Oxidative Med. Cell Longev.. 2017;2017 1273042. doi:10.1155/2017/1273042
166. White C.R., Anantharamaiah G.M.. Cholesterol reduction and macrophage function: Role of paraoxonases. Curr. Opin. Lipidol.. 2017;28 397–402. doi:10.1097/MOL.0000000000000444
167. Luyster F.S., Kip K.E., Drumheller O.J., Rice T.B., Edmundowicz D., Matthews K., et al.. Sleep apnea is related to the atherogenic phenotype, lipoprotein subclass B. J. Clin. Sleep Med.. 2012;8 155–161. doi:10.5664/jcsm.1768
168. Sopkova Z., Berneis K., Rizzo M., Spinas G.A., Dorkova Z., Tisko R., et al.. Size and Subclasses of Low-Density Lipoproteins in Patients With Obstructive Sleep Apnea. Angiology. 2012;63 617–621. doi:10.1177/0003319711433811
169. Liu A., Cardell J., Ariel D., Lamendola C., Abbasi F., Kim S.H., et al.. Abnormalities of lipoprotein concentrations in obstructive sleep apnea are related to insulin resistance. Sleep. 2015;38 793–799. doi:10.5665/sleep.4678
170. Feres M.C., Fonseca F.A., Cintra F.D., Mello-Fujita L., de Souza A.L., De Martino M.C., et al.. An assessment of oxidized LDL in the lipid profiles of patients with obstructive sleep apnea and its association with both hypertension and dyslipidemia, and the impact of treatment with CPAP. Atherosclerosis. 2015;241 342–349. doi:10.1016/j.atherosclerosis.2015.05.008
171. Tan K.C., Chow W.S., Lam J.C., Lam B., Wong W.K., Tam S., et al.. HDL dysfunction in obstructive sleep apnea. Atherosclerosis. 2006;184 377–382. doi:10.1016/j.atherosclerosis.2005.04.024
172. Kizawa T., Nakamura Y., Takahashi S., Sakurai S., Yamauchi K., Inoue H.. Pathogenic role of angiotensin II and oxidised LDL in obstructive sleep apnoea. Eur. Respir. J.. 2009;34 1390–1398. doi:10.1183/09031936.00009709
173. Tauman R., Lavie L., Greenfeld M., Sivan Y.. Oxidative stress in children with obstructive sleep apnea syndrome. J. Clin. Sleep Med.. 2014;10 677–681. doi:10.5664/jcsm.3800
174. Lee S.D., Ju G., Choi J.A., Kim J.W., Yoon I.Y.. The association of oxidative stress with central obesity in obstructive sleep apnea. Sleep Breath. 2012;16 511–517. doi:10.1007/s11325-011-0536-7
175. Svatikova A., Wolk R., Lerman L.O., Juncos L.A., Greene E.L., McConnell J.P., et al.. Oxidative stress in obstructive sleep apnoea. Eur. Heart J.. 2005;26 2435–2439. doi:10.1093/eurheartj/ehi440
176. Fadaei R., Safari-Faramani R., Rezaei M., Ahmadi R., Rostampour M., Moradi N., et al.. Circulating levels of oxidized low-density lipoprotein in patients with obstructive sleep apnea: A systematic review and meta-analysis. Sleep Breath. 2020;24 809–815. doi:10.1007/s11325-020-02089-y
177. Undurti A., Huang Y., Lupica J.A., Smith J.D., DiDonato J.A., Hazen S.L.. Modification of high density lipoprotein by myeloperoxidase generates a pro-inflammatory particle. J. Biol. Chem.. 2009;284 30825–30835. doi:10.1074/jbc.M109.047605
178. Rosenson R.S., Brewer H.B., Ansell B.J., Barter P., Chapman M.J., Heinecke J.W., et al.. Dysfunctional HDL and atherosclerotic cardiovascular disease. Nat. Rev. Cardiol.. 2016;13 48–60. doi:10.1038/nrcardio.2015.124
179. Cabana V.G., Lukens J.R., Rice K.S., Hawkins T.J., Getz G.S.. HDL content and composition in acute phase response in three species: Triglyceride enrichment of HDL a factor in its decrease. J. Lipid Res.. 1996;37 2662–2674. doi:10.1016/S0022-2275(20)37469-1
180. Song D., Fang G., Mao S.Z., Ye X., Liu G., Gong Y., et al.. Chronic intermittent hypoxia induces atherosclerosis by NF-κB-dependent mechanisms. Biochim. Biophys. Acta (BBA)-Mol. Basis Dis.. 2012;1822 1650–1659. doi:10.1016/j.bbadis.2012.07.010
181. Chen M., Li W., Wang N., Zhu Y., Wang X.. ROS and NF-kappaB but not LXR mediate IL-1beta signaling for the downregulation of ATP-binding cassette transporter A1. Am. J. Physiol. Cell Physiol.. 2007;292 C1493–C1501. doi:10.1152/ajpcell.00016.2006
182. Hanikoglu F., Huseyinoglu N., Ozben S., Cort A., Ozdem S., Ozben T.. Increased plasma soluble tumor necrosis factor receptor-1 and myeloperoxidase activity in patients with obstructive sleep apnea syndrome. Int. J. Neurosci.. 2015;125 655–662. doi:10.3109/00207454.2014.960521
183. Bergt C., Pennathur S., Fu X., Byun J., O’Brien K., McDonald T.O., et al.. The myeloperoxidase product hypochlorous acid oxidizes HDL in the human artery wall and impairs ABCA1-dependent cholesterol transport. Proc. Natl. Acad. Sci. USA. 2004;101 13032–13037. doi:10.1073/pnas.0405292101
184. Zheng L., Settle M., Brubaker G., Schmitt D., Hazen S.L., Smith J.D., et al.. Localization of nitration and chlorination sites on apolipoprotein A-I catalyzed by myeloperoxidase in human atheroma and associated oxidative impairment in ABCA1-dependent cholesterol efflux from macrophages. J. Biol. Chem.. 2005;280 38–47. doi:10.1074/jbc.M407019200
185. Gao D., Ashraf M.Z., Zhang L., Kar N., Byzova T.V., Podrez E.A.. Cross-linking modifications of HDL apoproteins by oxidized phospholipids: Structural characterization, in vivo detection, and functional implications. J. Biol. Chem.. 2020;295 1973–1984. doi:10.1074/jbc.RA119.008445
186. Pruzanski W., Stefanski E., de Beer F.C., de Beer M.C., Vadas P., Ravandi A., et al.. Lipoproteins are substrates for human secretory group IIA phospholipase A2: Preferential hydrolysis of acute phase HDL. J. Lipid Res.. 1998;39 2150–2160. doi:10.1016/S0022-2275(20)32470-6
187. Kar S., Patel M.A., Tripathy R.K., Bajaj P., Suvarnakar U.V., Pande A.H.. Oxidized phospholipid content destabilizes the structure of reconstituted high density lipoprotein particles and changes their function. Biochim. Biophys. Acta. 2012;1821 1200–1210. doi:10.1016/j.bbalip.2012.05.002
188. Jaouad L., Milochevitch C., Khalil A.. PON1 paraoxonase activity is reduced during HDL oxidation and is an indicator of HDL antioxidant capacity. Free Radic. Res.. 2003;37 77–83. doi:10.1080/1071576021000036614
189. Lavie L., Dyugovskaya L., Golan-Shany O., Lavie P.. Heat-shock protein 70: Expression in monocytes of patients with sleep apnoea and association with oxidative stress and tumour necrosis factor-alpha. J. Sleep Res.. 2010;19 139–147. doi:10.1111/j.1365-2869.2009.00789.x
190. Kotani K., Kimura S., Tsuzaki K., Sakane N., Komada I., Schulze J., et al.. Reduced paraoxonase 1/arylesterase activity and its post-therapeutic increase in obstructive sleep apnea syndrome: A preliminary study. Clin. Chim. Acta.. 2008;395 184–185. doi:10.1016/j.cca.2008.04.023
191. Lavie L., Vishnevsky A., Lavie P.. Evidence for lipid peroxidation in obstructive sleep apnea. Sleep. 2004;27 123–128.
192. Baysal E., Taysi S., Aksoy N., Uyar M., Celenk F., Karatas Z.A., et al.. Serum paraoxonase, arylesterase activity and oxidative status in patients with obstructive sleep apnea syndrome (OSAS). Eur. Rev. Med. Pharm. Sci.. 2012;16 770–774.
193. Płóciniczak A., Baszczuk A., Ludziejewska A., Winiarska H., Michalak S., Kasprzak G., et al.. Paraoxonase 1 gene L55M polymorphism and paraoxonase 1 activity in obstructive sleep apnea patients. Adv. Exp. Med. Biol.. 2019;1150 17–24. doi:10.1007/5584_2018_267
194. Shao B., Cavigiolio G., Brot N., Oda M.N., Heinecke J.W.. Methionine oxidation impairs reverse cholesterol transport by apolipoprotein A-I. Proc. Natl. Acad. Sci. USA. 2008;105 12224–12229. doi:10.1073/pnas.0802025105
195. Huang Y., DiDonato J.A., Levison B.S., Schmitt D., Li L., Wu Y., et al.. An abundant dysfunctional apolipoprotein A1 in human atheroma. Nat. Med.. 2014;20 193–203. doi:10.1038/nm.3459
196. Svatikova A., Wolk R., Shamsuzzaman A.S., Kara T., Olson E.J., Somers V.K.. Serum amyloid a in obstructive sleep apnea. Circulation. 2003;108 1451–1454. doi:10.1161/01.CIR.0000089091.09527.B8
197. Whitehead A.S., de Beer M.C., Steel D.M., Rits M., Lelias J.M., Lane W.S., et al.. Identification of novel members of the serum amyloid A protein superfamily as constitutive apolipoproteins of high density lipoprotein. J Biol. Chem.. 1992;267 3862–3867. doi:10.1016/S0021-9258(19)50605-6
198. Wroblewski J.M., Jahangiri A., Ji A., de Beer F.C., van der Westhuyzen D.R., Webb N.R.. Nascent HDL formation by hepatocytes is reduced by the concerted action of serum amyloid A and endothelial lipase. J. Lipid Res.. 2011;52 2255–2261. doi:10.1194/jlr.M017681
199. Nicholls S.J., Lundman P., Harmer J.A., Cutri B., Griffiths K.A., Rye K.A., et al.. Consumption of saturated fat impairs the anti-in.n.nflamma.atory properties of high-density lipoproteins and endothelial function. J. Am. Coll. Cardiol.. 2006;48 715–720. doi:10.1016/j.jacc.2006.04.080
200. Meszaros M., Horvath P., Kis A., Kunos L., Tarnoki A.D., Tarnoki D.L., et al.. Circulating levels of clusterin and complement factor H in patients with obstructive sleep apnea. Biomark. Med.. 2021;15 323–330. doi:10.2217/bmm-2020-0533
201. Peng Y., Zhou L., Cao Y., Chen P., Chen Y., Zong D., et al.. Relation between serum leptin levels, lipid profiles and neurocognitive deficits in Chinese OSAHS patients. Int. J. Neurosci.. 2017;127 981–987. doi:10.1080/00207454.2017.1286654
202. Roche F., Sforza E., Pichot V., Maudoux D., Garcin A., Celle S., et al.. Obstructive sleep apnoea/hypopnea influences high-density lipoprotein cholesterol in the elderly. Sleep Med.. 2009;10 882–886. doi:10.1016/j.sleep.2008.07.017
203. Drager L.F., Lopes H.F., Maki-Nunes C., Trombetta I.C., Toschi-Dias E., Alves M.J., et al.. The impact of obstructive sleep apnea on metabolic and inflammatory markers in consecutive patients with metabolic syndrome. PLoS ONE. 2010;5 doi:10.1371/journal.pone.0012065
204. Cai G., Shi G., Xue S., Lu W.. The atherogenic index of plasma is a strong and independent predictor for coronary artery disease in the Chinese Han population. Medicine. 2017;96 e8058. doi:10.1097/MD.0000000000008058
205. Shimizu Y., Yoshimine H., Nagayoshi M., Kadota K., Takahashi K., Izumino K., et al.. Serum triglyceride levels in relation to high-density lipoprotein cholesterol (TG-HDL) ratios as an efficient tool to estimate the risk of sleep apnea syndrome in non-overweight Japanese men. Environ. Health Prev. Med.. 2016;21 321–326. doi:10.1007/s12199-016-0532-4
206. Wu W.-T., Tsai S.-S., Shih T.-S., Lin M.-H., Chou T.-C., Ting H., et al.. The association between obstructive sleep apnea and metabolic markers and lipid profiles. PLoS ONE. 2015;10 e0130279. doi:10.1371/journal.pone.0130279
207. Cao B., Fan Z., Zhang Y., Li T.. Independent association of severity of obstructive sleep apnea with lipid metabolism of atherogenic index of plasma (AIP) and apoB/apoAI ratio. Sleep Breath. 2020;24 1507–1513. doi:10.1007/s11325-020-02016-1
208. Silva L.O.E., Guimarães T.M., Luz G.P., Coelho G., Badke L., Almeida I.R., et al.. Metabolic profile in patients with mild obstructive sleep apnea. Metab. Syndr. Relat. Disord.. 2018;16 6–12. doi:10.1089/met.2017.0075
209. Bikov A., Meszaros M., Kunos L., Negru A.G., Frent S.M., Mihaicuta S.. Atherogenic Index of Plasma in Obstructive Sleep Apnoea. J. Clin. Med.. 2021;10 doi:10.3390/jcm10030417
210. Bays H.E., González-Campoy J.M., Bray G.A., Kitabchi A.E., Bergman D.A., Schorr A.B., et al.. Pathogenic potential of adipose tissue and metabolic consequences of adipocyte hypertrophy and increased visceral adiposity. Expert Rev. Cardiovasc. Ther.. 2008;6 343–368. doi:10.1586/14779072.6.3.343
211. Haemmerle G., Lass A., Zimmermann R., Gorkiewicz G., Meyer C., Rozman J., et al.. Defective lipolysis and altered energy metabolism in mice lacking adipose triglyceride lipase. Science. 2006;312 734–737. doi:10.1126/science.1123965
212. Reynisdottir S., Dauzats M., Thörne A., Langin D.. Comparison of hormone-sensitive lipase activity in visceral and subcutaneous human adipose tissue. J. Clin. Endocrinol. Metab.. 1997;82 4162–4166. doi:10.1210/jc.82.12.4162
213. Fredrikson G., Tornqvist H., Belfrage P.. Hormone-sensitive lipase and monoacylglycerol lipase are both required for complete degradation of adipocyte triacylglycerol. Biochim. Biophys. Acta. 1986;876 288–293. doi:10.1016/0005-2760(86)90286-9
214. Chalacheva P., Thum J., Yokoe T., O’Donnell C.P., Khoo M.C.. Development of autonomic dysfunction with intermittent hypoxia in a lean murine model. Respir. Physiol. Neurobiol.. 2013;188 143–151. doi:10.1016/j.resp.2013.06.002
215. Carpéné C., Bousquet-Mélou A., Galitzky J., Berlan M., Lafontan M.. Lipolytic effects of beta 1-, beta 2-, and beta 3-adrenergic agonists in white adipose tissue of mammals. Ann. N. Y. Acad. Sci.. 1998;839 186–189. doi:10.1111/j.1749-6632.1998.tb10756.x
216. Netchitaïlo M., Fabre F., Briançon A., Belaidi-Corsat E., Arnaud C., Borel A.-L., et al.. Two weeks of intermittent hypoxic exposure induce lipolysis at the fat tissue level in healthy human subjects. Eur. Respir. J.. 2017;50 PA2968.
217. Weiszenstein M., Shimoda L.A., Koc M., Seda O., Polak J.. Inhibition of Lipolysis Ameliorates Diabetic Phenotype in a Mouse Model of Obstructive Sleep Apnea. Am. J. Respir. Cell Mol. Biol.. 2016;55 299–307. doi:10.1165/rcmb.2015-0315OC
218. Musutova M., Weiszenstein M., Koc M., Polak J.. Intermittent hypoxia stimulates lipolysis, but inhibits differentiation and de novo lipogenesis in 3T3-L1 cells. Metab. Syndr. Relat. Disord.. 2020;18 146–153. doi:10.1089/met.2019.0112
219. Krawczyk S.A., Haller J.F., Ferrante T., Zoeller R.A., Corkey B.E.. Reactive oxygen species facilitate translocation of hormone sensitive lipase to the lipid droplet during lipolysis in human differentiated adipocytes. PLoS ONE. 2012;7 e34904. doi:10.1371/journal.pone.0034904
220. Wang H., Bell M., Sreenivasan U., Sreenevasan U., Hu H., Liu J., et al.. Unique regulation of adipose triglyceride lipase (ATGL) by perilipin 5, a lipid droplet-associated protein. J. Biol. Chem.. 2011;286 15707–15715. doi:10.1074/jbc.M110.207779
221. Ryden M., Dicker A., van Harmelen V., Hauner H., Brunnberg M., Perbeck L., et al.. Mapping of early signaling events in tumor necrosis factor-alpha -mediated lipolysis in human fat cells. J. Biol. Chem.. 2002;277 1085–1091. doi:10.1074/jbc.M109498200
222. van Hall G., Steensberg A., Sacchetti M., Fischer C., Keller C., Schjerling P., et al.. Interleukin-6 stimulates lipolysis and fat oxidation in humans. J. Clin. Endocrinol. Metab.. 2003;88 3005–3010. doi:10.1210/jc.2002-021687
223. Cao Y., Song Y., Ning P., Zhang L., Wu S., Quan J., et al.. Association between tumor necrosis factor alpha and obstructive sleep apnea in adults: A meta-analysis update. BMC Pulm. Med.. 2020;20 doi:10.1186/s12890-020-01253-0
224. Imani M.M., Sadeghi M., Khazaie H., Emami M., Sadeghi Bahmani D., Brand S.. Evaluation of Serum and Plasma Interleukin-6 Levels in Obstructive Sleep Apnea Syndrome: A Meta-Analysis and Meta-Regression. Front. Immunol.. 2020;11 1343. doi:10.3389/fimmu.2020.01343
225. Briançon-Marjollet A., Monneret D., Henri M., Hazane-Puch F., Pepin J.L., Faure P., et al.. Endothelin regulates intermittent hypoxia-induced lipolytic remodelling of adipose tissue and phosphorylation of hormone-sensitive lipase. J. Physiol.. 2016;594 1727–1740. doi:10.1113/JP271321
226. Shen W.J., Sridhar K., Bernlohr D.A., Kraemer F.B.. Interaction of rat hormone-sensitive lipase with adipocyte lipid-binding protein. Proc. Natl. Acad. Sci. USA. 1999;96 5528–5532. doi:10.1073/pnas.96.10.5528
227. Català R., Cabré A., Hernández-Flix S., Ferré R., Sangenís S., Plana N., et al.. Circulating FABP4 and FABP5 levels are differently linked to OSA severity and treatment. Sleep. 2013;36 1831–1837. doi:10.5665/sleep.3210
228. Lam D.C., Xu A., Lam K.S., Lam B., Lam J.C., Lui M.M., et al.. Serum adipocyte-fatty acid binding protein level is elevated in severe OSA and correlates with insulin resistance. Eur. Respir. J.. 2009;33 346–351. doi:10.1183/09031936.50075408
229. Balci M.M., Arslan U., Firat H., Kocaoğlu I., Vural M.G., Balci K.G., et al.. Serum levels of adipocyte fatty acid-binding protein are independently associated with left ventricular mass and myocardial performance index in obstructive sleep apnea syndrome. J. Investig. Med.. 2012;60 1020–1026. doi:10.2310/JIM.0b013e31826868f2
230. Hofer P., Boeszoermenyi A., Jaeger D., Feiler U., Arthanari H., Mayer N., et al.. Fatty Acid-binding Proteins Interact with Comparative Gene Identification-58 Linking Lipolysis with Lipid Ligand Shuttling *. J. Biol. Chem.. 2015;290 18438–18453. doi:10.1074/jbc.M114.628958
231. Gordon E.S.. Non-Esterified Fatty Acids in the Blood of Obese and Lean Subjects. Am. J. Clin. Nutr.. 1960;8 740–747. doi:10.1093/ajcn/8.5.740
232. Frühbeck G., Gómez-Ambrosi J., Salvador J.. Leptin-induced lipolysis opposes the tonic inhibition of endogenous adenosine in white adipocytes. FASEB J.. 2001;15 333–340. doi:10.1096/fj.00-0249com
233. Wedellová Z., Dietrich J., Siklová-Vítková M., Kološtová K., Kováčiková M., Dušková M., et al.. Adiponectin inhibits spontaneous and catecholamine-induced lipolysis in human adipocytes of non-obese subjects through AMPK-dependent mechanisms. Physiol. Res.. 2011;60 139–148. doi:10.33549/physiolres.931863
234. Kapsimalis F., Varouchakis G., Manousaki A., Daskas S., Nikita D., Kryger M., et al.. Association of sleep apnea severity and obesity with insulin resistance, C-reactive protein, and leptin levels in male patients with obstructive sleep apnea. Lung. 2008;186 209–217. doi:10.1007/s00408-008-9082-x
235. Tokuda F., Sando Y., Matsui H., Koike H., Yokoyama T.. Serum levels of adipocytokines, adiponectin and leptin, in patients with obstructive sleep apnea syndrome. Intern. Med.. 2008;47 1843–1849. doi:10.2169/internalmedicine.47.1035
236. Ormazabal V., Nair S., Elfeky O., Aguayo C., Salomon C., Zuñiga F.A.. Association between insulin resistance and the development of cardiovascular disease. Cardiovasc. Diabetol.. 2018;17 122. doi:10.1186/s12933-018-0762-4
237. Pasarica M., Rood J., Ravussin E., Schwarz J.-M., Smith S.R., Redman L.M.. Reduced oxygenation in human obese adipose tissue is associated with impaired insulin suppression of lipolysis. J. Clin. Endocrinol. Metab.. 2010;95 4052–4055. doi:10.1210/jc.2009-2377
238. Rooney K., Trayhurn P.. Lactate and the GPR81 receptor in metabolic regulation: Implications for adipose tissue function and fatty acid utilisation by muscle during exercise. Br. J. Nutr.. 2011;106 1310–1316. doi:10.1017/S0007114511004673
239. Späth-Schwalbe E., Gofferje M., Kern W., Born J., Fehm H.L.. Sleep disruption alters nocturnal ACTH and cortisol secretory patterns. Biol. Psychiatry. 1991;29 575–584. doi:10.1016/0006-3223(91)90093-2
240. Brindley D.N., McCann B.S., Niaura R., Stoney C.M., Suarez E.C.. Stress and lipoprotein metabolism: M odulators and mechanisms. Metabolism. 1993;42 3–15. doi:10.1016/0026-0495(93)90255-M
241. Young T., Palta M., Dempsey J., Skatrud J., Weber S., Badr S.. The occurrence of sleep-disordered breathing among middle-aged adults. N. Engl. J. Med.. 1993;328 1230–1235. doi:10.1056/NEJM199304293281704
242. Peppard P.E., Young T., Palta M., Dempsey J., Skatrud J.. Longitudinal study of moderate weight change and sleep-disordered breathing. Jama. 2000;284 3015–3021. doi:10.1001/jama.284.23.3015
243. Ryan S., Arnaud C., Fitzpatrick S.F., Gaucher J., Tamisier R., Pépin J.-L.. Adipose tissue as a key player in obstructive sleep apnoea. Eur. Respir. Rev.. 2019;28 190006. doi:10.1183/16000617.0006-2019
244. Jo J., Gavrilova O., Pack S., Jou W., Mullen S., Sumner A.E., et al.. Hypertrophy and/or hyperplasia: Dynamics of adipose tissue growth. PLoS Comput. Biol.. 2009;5 doi:10.1371/journal.pcbi.1000324
245. Cildir G., Akıncılar S.C., Tergaonkar V.. Chronic adipose tissue inflammation: All immune cells on the stage. Trends Mol. Med.. 2013;19 487–500. doi:10.1016/j.molmed.2013.05.001
246. Ryan S.. Adipose tissue inflammation by intermittent hypoxia: Mechanistic link between obstructive sleep apnoea and metabolic dysfunction. J. Physiol.. 2017;595 2423–2430. doi:10.1113/JP273312
247. Poulain L., Thomas A., Rieusset J., Casteilla L., Levy P., Arnaud C., et al.. Visceral white fat remodelling contributes to intermittent hypoxia-induced atherogenesis. Eur. Respir. J.. 2014;43 513. doi:10.1183/09031936.00019913
248. Poulain L., Richard V., Lévy P., Dematteis M., Arnaud C.. Toll-like receptor-4 mediated inflammation is involved in the cardiometabolic alterations induced by intermittent hypoxia. Mediat. Inflamm.. 2015;2015 620258. doi:10.1155/2015/620258
249. Briançon-Marjollet A., Pépin J.L., Weiss J.W., Lévy P., Tamisier R.. Intermittent hypoxia upregulates serum VEGF. Sleep Med.. 2014;15 1425–1426. doi:10.1016/j.sleep.2014.07.006
250. Murphy A.M., Thomas A., Crinion S.J., Kent B.D., Tambuwala M.M., Fabre A., et al.. Intermittent hypoxia in obstructive sleep apnoea mediates insulin resistance through adipose tissue inflammation. Eur. Respir. J.. 2017;49 1601731. doi:10.1183/13993003.01731-2016
251. Kanda H., Tateya S., Tamori Y., Kotani K., Hiasa K., Kitazawa R., et al.. MCP-1 contributes to macrophage infiltration into adipose tissue, insulin resistance, and hepatic steatosis in obesity. J. Clin. Investig.. 2006;116 1494–1505. doi:10.1172/JCI26498
252. Kim J., Lee C.H., Park C.S., Kim B.G., Kim S.W., Cho J.H.. Plasma levels of MCP-1 and adiponectin in obstructive sleep apnea syndrome. Arch. Otolaryngol. Head Neck Surg.. 2010;136 896–899. doi:10.1001/archoto.2010.142
253. Fanfulla F., Rotondi M., Morrone E., Coperchini F., Lodigiani S., Trentin R., et al.. Sleep hypoxia and not obesity is the main determinant of the increasing monocyte chemoattractant protein-1 (MCP-1) in patients with obstructive sleep apnoea. ERJ Open Res.. 2017;3 P70.
254. Taylor C.T., Kent B.D., Crinion S.J., McNicholas W.T., Ryan S.. Human adipocytes are highly sensitive to intermittent hypoxia induced NF-kappaB activity and subsequent inflammatory gene expression. Biochem. Biophys Res. Commun.. 2014;447 660–665. doi:10.1016/j.bbrc.2014.04.062
255. Mishra S., Harris T.B., Hue T., Miljkovic I., Satterfield S., de Rekeneire N., et al.. Hyperleptinemia, adiposity, and risk of metabolic syndrome in older adults. J. Nutr. Metab.. 2013;2013 327079. doi:10.1155/2013/327079
256. Welsh P., Murray H.M., Buckley B.M., de Craen A.J.M., Ford I., Jukema J.W., et al.. Leptin predicts diabetes but not cardiovascular disease: Results from a large prospective study in an elderly population. Diabetes Care. 2009;32 308–310. doi:10.2337/dc08-1458
257. Sierra-Johnson J., Romero-Corral A., Lopez-Jimenez F., Gami A.S., Sert Kuniyoshi F.H., Wolk R., et al.. Relation of increased leptin concentrations to history of myocardial infarction and stroke in the United States population. Am. J. Cardiol.. 2007;100 234–239. doi:10.1016/j.amjcard.2007.02.088
258. Ku I.A., Farzaneh-Far R., Vittinghoff E., Zhang M.H., Na B., Whooley M.A.. Association of low leptin with cardiovascular events and mortality in patients with stable coronary artery disease: The Heart and Soul Study. Atherosclerosis. 2011;217 503–508. doi:10.1016/j.atherosclerosis.2010.10.047
259. Schäfer H., Pauleit D., Sudhop T., Gouni-Berthold I., Ewig S., Berthold H.K.. Body fat distribution, serum leptin, and cardiovascular risk factors in men with obstructive sleep apnea. Chest. 2002;122 829–839. doi:10.1378/chest.122.3.829
260. Ozturk L., Unal M., Tamer L., Celikoglu F.. The association of the severity of obstructive sleep apnea with plasma leptin levels. Arch. Otolaryngol. Head Neck Surg.. 2003;129 538–540. doi:10.1001/archotol.129.5.538
261. Tatsumi K., Kasahara Y., Kurosu K., Tanabe N., Takiguchi Y., Kuriyama T.. Sleep oxygen desaturation and circulating leptin in obstructive sleep apnea-hyp.p.p.popnea syndrome. Chest. 2005;127 716–721. doi:10.1378/chest.127.3.716
262. McArdle N., Hillman D., Beilin L., Watts G.. Metabolic risk factors for vascular disease in obstructive sleep apnea: A matched controlled study. Am. J. Respir. Crit. Care Med.. 2007;175 190–195. doi:10.1164/rccm.200602-270OC
263. Hirotsu C., Albuquerque R.G., Nogueira H., Hachul H., Bittencourt L., Tufik S., et al.. The relationship between sleep apnea, metabolic dysfunction and inflammation: The gender influence. Brain Behav. Immun.. 2017;59 211–218. doi:10.1016/j.bbi.2016.09.005
264. Arnardottir E.S., Maislin G., Jackson N., Schwab R.J., Benediktsdottir B., Teff K., et al.. The role of obesity, different fat compartments and sleep apnea severity in circulating leptin levels: The Icelandic Sleep Apnea Cohort study. Int. J. Obes.. 2013;37 835–842. doi:10.1038/ijo.2012.138
265. Knight Z.A., Hannan K.S., Greenberg M.L., Friedman J.M.. Hyperleptinemia is required for the development of leptin resistance. PLoS ONE. 2010;5 doi:10.1371/journal.pone.0011376
266. Berger S., Polotsky V.Y.. Leptin and leptin resistance in the pathogenesis of obstructive sleep apnea: A possible link to oxidative stress and cardiovascular complications. Oxidative Med. Cell Longev.. 2018;2018 5137947. doi:10.1155/2018/5137947
267. Ciriello J., Moreau J.M., Caverson M.M., Moranis R.. Leptin: A Potential Link Between Obstructive Sleep Apnea and Obesity. Front. Physiol.. 2022;12 767318. doi:10.3389/fphys.2021.767318
268. Pan W., Kastin A.J.. Leptin: A biomarker for sleep disorders?. Sleep Med. Rev.. 2014;18 283–290. doi:10.1016/j.smrv.2013.07.003
269. Gonnissen H.K., Hursel R., Rutters F., Martens E.A., Westerterp-Plantenga M.S.. Effects of sleep fragmentation on appetite and related hormone concentrations over 24 h in healthy men. Br. J. Nutr.. 2013;109 748–756. doi:10.1017/S0007114512001894
270. Framnes S.N., Arble D.M.. The Bidirectional Relationship Between Obstructive Sleep Apnea and Metabolic Disease. Front. Endocrinol.. 2018;9 440. doi:10.3389/fendo.2018.00440
271. Grosfeld A., Andre J., Hauguel-De Mouzon S., Berra E., Pouyssegur J., Guerre-Millo M.. Hypoxia-inducible factor 1 transactivates the human leptin gene promoter. J. Biol. Chem.. 2002;277 42953–42957. doi:10.1074/jbc.M206775200
272. Gallardo N., Bonzón-Kulichenko E., Fernández-Agulló T., Moltó E., Gómez-Alonso S., Blanco P., et al.. Tissue-specific effects of central leptin on the expression of genes involved in lipid metabolism in liver and white adipose tissue. Endocrinology. 2007;148 5604–5610. doi:10.1210/en.2007-0933
273. Brabant G., Müller G., Horn R., Anderwald C., Roden M., Nave H.. Hepatic leptin signaling in obesity. FASEB J.. 2005;19 1048–1050. doi:10.1096/fj.04-2846fje
274. Sertogullarindan B., Komuroglu A.U., Ucler R., Gunbatar H., Sunnetcioglu A., Cokluk E.. Betatrophin association with serum triglyceride levels in obstructive sleep apnea patients. Ann. Thorac. Med.. 2019;14 63–68. doi:10.4103/atm.ATM_52_18
275. Morawietz H., Bornstein S.R.. Leptin, Endothelin, NADPH Oxidase, and Heart Failure. Hypertension. 2006;47 e20–e21. doi:10.1161/01.HYP.0000218452.18010.fb
276. Pilz S., Horejsi R., Möller R., Almer G., Scharnagl H., Stojakovic T., et al.. Early atherosclerosis in obese juveniles is associated with low serum levels of adiponectin. J. Clin. Endocrinol. Metab.. 2005;90 4792–4796. doi:10.1210/jc.2005-0167
277. Kim D.H., Kim C., Ding E.L., Townsend M.K., Lipsitz L.A.. Adiponectin levels and the risk of hypertension: A systematic review and meta-analysis. Hypertension. 2013;62 27–32. doi:10.1161/HYPERTENSIONAHA.113.01453
278. Lu M., Fang F., Wang Z., Wei P., Hu C., Wei Y.. Association between serum/plasma levels of adiponectin and obstructive sleep apnea hypopnea syndrome: A meta-analysis. Lipids Health Dis.. 2019;18 30. doi:10.1186/s12944-019-0973-z
279. Domagała-Kulawik J., Osińska I., Piechuta A., Bielicki P., Skirecki T.. T, B, and NKT Cells in Systemic Inflammation in Obstructive Sleep Apnoea. Mediat. Inflamm.. 2015;2015 161579. doi:10.1155/2015/161579
280. Zhang D.-M., Pang X.-L., Huang R., Gong F.-Y., Zhong X., Xiao Y.. Adiponectin, Omentin, Ghrelin, and Visfatin Levels in Obese Patients with Severe Obstructive Sleep Apnea. Biomed. Res. Int.. 2018;2018 3410135. doi:10.1155/2018/3410135
281. Gonzalez F.J., Xie C., Jiang C.. The role of hypoxia-inducible factors in metabolic diseases. Nat. Rev. Endocrinol.. 2018;15 21–32. doi:10.1038/s41574-018-0096-z
282. Oku H., Matsuura F., Koseki M., Sandoval J.C., Yuasa-Kawase M., Tsubakio-Yamamoto K., et al.. Adiponectin deficiency suppresses ABCA1 expression and ApoA-I synthesis in the liver. FEBS Lett.. 2007;581 5029–5033. doi:10.1016/j.febslet.2007.09.038
283. Matsuura F., Oku H., Koseki M., Sandoval J.C., Yuasa-Kawase M., Tsubakio-Yamamoto K., et al.. Adiponectin accelerates reverse cholesterol transport by increasing high density lipoprotein assembly in the liver. Biochem. Biophys. Res. Commun.. 2007;358 1091–1095. doi:10.1016/j.bbrc.2007.05.040
284. Matsubara M., Maruoka S., Katayose S.. Decreased plasma adiponectin concentrations in women with dyslipidemia. J. Clin. Endocrinol. Metab.. 2002;87 2764–2769. doi:10.1210/jcem.87.6.8550
285. Kobayashi J., Kusunoki M., Murase Y., Kawashiri M., Higashikata T., Miwa K., et al.. Relationship of lipoprotein lipase and hepatic triacylglycerol lipase activity to serum adiponectin levels in Japanese hyperlipidemic men. Horm. Metab. Res.. 2005;37 505–509. doi:10.1055/s-2005-870318
286. Qiao L., Zou C., van der Westhuyzen D.R., Shao J.. Adiponectin reduces plasma triglyceride by increasing VLDL triglyceride catabolism. Diabetes. 2008;57 1824–1833. doi:10.2337/db07-0435
287. Yoshida H., Hirowatari Y., Kurosawa H., Tada N.. Implications of decreased serum adiponectin for type IIb hyperlipidaemia and increased cholesterol levels of very-low-density lipoprotein in type II diabetic patients. Clin. Sci.. 2005;109 297–302. doi:10.1042/CS20040353
288. Møller N., Gjedsted J., Gormsen L., Fuglsang J., Djurhuus C.. Effects of growth hormone on lipid metabolism in humans. Growth Horm. IGF Res.. 2003;13 S18–S21. doi:10.1016/S1096-6374(03)00048-0
289. Brindley D.N.. Role of glucocorticoids and fatty acids in the impairment of lipid metabolism observed in the metabolic syndrome. Int. J. Obes. Relat. Metab. Disord.. 1995;19 S69–S75.
290. Williamson D.H.. Role of insulin in the integration of lipid metabolism in mammalian tissues. Biochem. Soc. Trans.. 1989;17 37–40. doi:10.1042/bst0170037
291. Christ E.R., Cummings M.H., Russell-Jones D.L.. Dyslipidaemia in Adult Growth Hormone (GH) Deficiency and the Effect of GH Replacement Therapy: A Review. Trends Endocrinol. Metab.. 1998;9 200–206. doi:10.1016/S1043-2760(98)00050-2
292. Lanfranco F., Motta G., Minetto M.A., Ghigo E., Maccario M.. Growth hormone/insulin-like growth factor-I axis in obstructive sleep apnea syndrome: An update. J. Endocrinol. Investig.. 2010;33 192–196. doi:10.1007/BF03346580
293. Whitworth J.A., Williamson P.M., Mangos G., Kelly J.J.. Cardiovascular consequences of cortisol excess. Vasc. Health Risk Manag.. 2005;1 291–299. doi:10.2147/vhrm.2005.1.4.291
294. Kritikou I., Basta M., Vgontzas A.N., Pejovic S., Fernandez-Mendoza J., Liao D., et al.. Sleep apnoea and the hypothalamic–pituitary–adrenal axis in men and women: Effects of continuous positive airway pressure. Eur. Respir. J.. 2016;47 531. doi:10.1183/13993003.00319-2015
295. Somers V.K., Dyken M.E., Mark A.L., Abboud F.M.. Sympathetic-nerve activity during sleep in normal subjects. N. Engl. J. Med.. 1993;328 303–307. doi:10.1056/NEJM199302043280502
296. Spiegel K., Leproult R., Van Cauter E.. Impact of sleep debt on metabolic and endocrine function. Lancet. 1999;354 1435–1439. doi:10.1016/S0140-6736(99)01376-8
297. Takahashi Y., Kipnis D.M., Daughaday W.H.. Growth hormone secretion during sleep. J. Clin. Investig.. 1968;47 2079–2090. doi:10.1172/JCI105893
298. Alzoubaidi M., Mokhlesi B.O.O.. Obstructive sleep apnea during rapid eye movement sleep: Clinical relevance and therapeutic implications. Curr. Opin. Pulm. Med.. 2016;22 545–554. doi:10.1097/MCP.0000000000000319
299. Bikov A., Lazar Z., Horvath P., Tarnoki D.L., Tarnoki A.D., Fesus L., et al.. Association Between Serum Lipid Profile and Obstructive Respiratory Events During REM and Non-REM Sleep. Lung. 2019;197 443–450. doi:10.1007/s00408-019-00195-7
300. Uchida T., Nishimura A., Kasai T., Kikuno S., Nagasawa K., Okubo M., et al.. Relationship between obstructive sleep apnoea during rapid eye movement sleep and metabolic syndrome parameters in patients with type 2 diabetes mellitus. Sleep Breath. 2021;25 309–314. doi:10.1007/s11325-020-02129-7
301. Xu H., Xia Y., Li X., Qian Y., Zou J., Fang F., et al.. Association between obstructive sleep apnea and lipid metabolism during REM and NREM sleep. J. Clin. Sleep Med.. 2020;16 475–482. doi:10.5664/jcsm.8242
302. Martínez-Cerón E., Casitas R., Galera R., Sánchez-Sánchez B., Zamarrón E., Garcia-Sanchez A., et al.. Contribution of sleep characteristics to the association between obstructive sleep apnea and dyslipidemia. Sleep Med.. 2021;84 63–72. doi:10.1016/j.sleep.2021.05.012
303. Coulet F., Nadaud S., Agrapart M., Soubrier F.. Identification of hypoxia-response element in the human endothelial nitric-oxide synthase gene promoter. J. Biol. Chem.. 2003;278 46230–46240. doi:10.1074/jbc.M305420200
304. Wang B., Yan B., Song D., Ye X., Liu S.F.. Chronic intermittent hypoxia down-regulates endothelial nitric oxide synthase expression by an NF-κB-dependent mechanism. Sleep Med.. 2013;14 165–171. doi:10.1016/j.sleep.2012.10.020
305. Kuzkaya N., Weissmann N., Harrison D.G., Dikalov S.. Interactions of peroxynitrite, tetrahydrobiopterin, ascorbic acid, and thiols: Implications for uncoupling endothelial nitric-oxide synthase. J. Biol. Chem.. 2003;278 22546–22554. doi:10.1074/jbc.M302227200
306. Vásquez-Vivar J., Kalyanaraman B., Martásek P., Hogg N., Masters B.S., Karoui H., et al.. Superoxide generation by endothelial nitric oxide synthase: The influence of cofactors. Proc. Natl. Acad. Sci. USA. 1998;95 9220–9225. doi:10.1073/pnas.95.16.9220
307. Jelic S., Padeletti M., Kawut S.S.S.S.S.M., Higgins C., Canfield S.M., Onat D., et al.. Inflammation, oxidative stress, and repair capacity of the vascular endothelium in obstructive sleep apnea. Circulation. 2008;117 2270–2278. doi:10.1161/CIRCULATIONAHA.107.741512
308. Lee W.J., Ou H.C., Hsu W.C., Chou M.M., Tseng J.J., Hsu S.L., et al.. Ellagic acid inhibits oxidized LDL-mediated LOX-1 expression, ROS generation, and inflammation in human endothelial cells. J. Vasc. Surg.. 2010;52 1290–1300. doi:10.1016/j.jvs.2010.04.085
309. Wang W., Hein T.W., Zhang C., Zawieja D.C., Liao J.C., Kuo L.. Oxidized low-density lipoprotein inhibits nitric oxide-mediated coronary arteriolar dilation by up-regulating endothelial arginase I. Microcirculation. 2011;18 36–45. doi:10.1111/j.1549-8719.2010.00066.x
310. Kattoor A.J., Pothineni N.V.K., Palagiri D., Mehta J.L.. Oxidative Stress in Atherosclerosis. Curr. Atheroscler. Rep.. 2017;19 42. doi:10.1007/s11883-017-0678-6
311. Williams A., Scharf S.M.. Obstructive sleep apnea, cardiovascular disease, and inflammation--is NF-kappaB the key?. Sleep Breath. 2007;11 69–76. doi:10.1007/s11325-007-0106-1
312. Horváth P., Lázár Z., Gálffy G., Puskás R., Kunos L., Losonczy G., et al.. Circulating P-Selectin Glycoprotein Ligand 1 and P-Selectin Levels in Obstructive Sleep Apnea Patients. Lung. 2020;198 173–179. doi:10.1007/s00408-019-00299-0
313. Pak V.M., Keenan B.T., Jackson N., Grandner M.A., Maislin G., Teff K., et al.. Adhesion molecule increases in sleep apnea: Beneficial effect of positive airway pressure and moderation by obesity. Int. J. Obes.. 2015;39 472–479. doi:10.1038/ijo.2014.123
314. Galkina E., Ley K.. Leukocyte influx in atherosclerosis. Curr. Drug Targets. 2007;8 1239–1248. doi:10.2174/138945007783220650
315. Kattoor A.J., Goel A., Mehta J.L.. LOX-1: Regulation, Signaling and Its Role in Atherosclerosis. Antioxidants. 2019;8 doi:10.3390/antiox8070218
316. Oh J., Riek A.E., Weng S., Petty M., Kim D., Colonna M., et al.. Endoplasmic reticulum stress controls M2 macrophage differentiation and foam cell formation. J. Biol. Chem.. 2012;287 11629–11641. doi:10.1074/jbc.M111.338673
317. Tontonoz P., Nagy L., Alvarez J.G., Thomazy V.A., Evans R.M.. PPARgamma promotes monocyte/macrophage differentiation and uptake of oxidized LDL. Cell. 1998;93 241–252. doi:10.1016/S0092-8674(00)81575-5
318. Tall A.R., Yvan-Charvet L.. Cholesterol, inflammation and innate immunity. Nat. Rev. Immunol.. 2015;15 104–116. doi:10.1038/nri3793
319. Kobiyama K., Ley K.. Atherosclerosis: A Chronic Inflammatory Disease with an Autoimmune Component. Circ. Res.. 2018;123 1118–1120. doi:10.1161/CIRCRESAHA.118.313816
320. Nofer J.-R., van der Giet M., Tölle M., Wolinska I., von Wnuck Lipinski K., Baba H.A., et al.. HDL induces NO-dependent vasorelaxation via the lysophospholipid receptor S1P3. J. Clin. Investig.. 2004;113 569–581. doi:10.1172/JCI200418004
321. Kimura T., Sato K., Kuwabara A., Tomura H., Ishiwara M., Kobayashi I., et al.. Sphingosine 1-phosphate may be a major component of plasma lipoproteins responsible for the cytoprotective actions in human umbilical vein endothelial cells. J. Biol. Chem.. 2001;276 31780–31785. doi:10.1074/jbc.M104353200
322. Kontush A., Therond P., Zerrad A., Couturier M., Négre-Salvayre A., de Souza J.A., et al.. Preferential Sphingosine-1-Phosphate Enrichment and Sphingomyelin Depletion Are Key Features of Small Dense HDL3 Particles. Arterioscler. Thromb. Vasc. Biol.. 2007;27 1843–1849. doi:10.1161/ATVBAHA.107.145672
323. Li X.A., Titlow W.B., Jackson B.A., Giltiay N., Nikolova-Karakashian M., Uittenbogaard A., et al.. High density lipoprotein binding to scavenger receptor, Class B, type I activates endothelial nitric-oxide synthase in a ceramide-dependent manner. J. Biol. Chem.. 2002;277 11058–11063. doi:10.1074/jbc.M110985200
324. Nofer J.R., Brodde M.F., Kehrel B.E.. High-density lipoproteins, platelets and the pathogenesis of atherosclerosis. Clin. Exp. Pharm. Physiol.. 2010;37 726–735. doi:10.1111/j.1440-1681.2010.05377.x
325. Kim J.K., Fillmore J.J., Chen Y.Y., Yu C., Moore I.K., Pypaert M., et al.. Tissue-specific overexpression of lipoprotein lipase causes tissue-specific insulin resistance. Proc. Natl. Acad. Sci. USA. 2001;98 7522–7527. doi:10.1073/pnas.121164498
326. Boden G.. Obesity, insulin resistance and free fatty acids. Curr. Opin. Endocrinol. Diabetes Obes.. 2011;18 139–143. doi:10.1097/MED.0b013e3283444b09
327. Patil Susheel P., Ayappa Indu A., Caples Sean M., Kimoff R.J., Patel Sanjay R., Harrod Christopher G.. Treatment of Adult Obstructive Sleep Apnea with Positive Airway Pressure: An American Academy of Sleep Medicine Clinical Practice Guideline. J. Clin. Sleep Med.. 2019;15 335–343. doi:10.5664/jcsm.7640
328. Ip M.S., Lam K.S., Ho C., Tsang K.W., Lam W.. Serum leptin and vascular risk factors in obstructive sleep apnea. Chest. 2000;118 580–586. doi:10.1378/chest.118.3.580
329. Robinson G.V., Pepperell J.C., Segal H.C., Davies R.J., Stradling J.R.. Circulating cardiovascular risk factors in obstructive sleep apnoea: Data from randomised controlled trials. Thorax. 2004;59 777–782. doi:10.1136/thx.2003.018739
330. Börgel J., Sanner B.M., Bittlinsky A., Keskin F., Bartels N.K., Buechner N., et al.. Obstructive sleep apnoea and its therapy influence high-density lipoprotein cholesterol serum levels. Eur. Respir. J.. 2006;27 121–127. doi:10.1183/09031936.06.00131304
331. Dorkova Z., Petrasova D., Molcanyiova A., Popovnakova M., Tkacova R.. Effects of Continuous Positive Airway Pressure on Cardiovascular Risk Profile in Patients With Severe Obstructive Sleep Apnea and Metabolic Syndrome. Chest. 2008;134 686–692. doi:10.1378/chest.08-0556
332. Barceló A., Barbé F., de la Peña M., Martinez P., Soriano J.B., Piérola J., et al.. Insulin resistance and daytime sleepiness in patients with sleep apnoea. Thorax. 2008;63 946–950. doi:10.1136/thx.2007.093740
333. Coughlin S.R., Mawdsley L., Mugarza J.A., Wilding J.P., Calverley P.M.. Cardiovascular and metabolic effects of CPAP in obese males with OSA. Eur. Respir. J.. 2007;29 720–727. doi:10.1183/09031936.00043306
334. Lattimore J.L., Wilcox I., Skilton M., Langenfeld M., Celermajer D.S.. Treatment of obstructive sleep apnoea leads to improved microvascular endothelial func.c.ction in the systemic circulation. Thorax. 2006;61 491–495. doi:10.1136/thx.2004.039164
335. Kitahara Y., Hattori N., Yokoyama A., Nakajima M., Kohno N.. Effect of CPAP on brachial-ankle pulse wave velocity in patients with OSAHS: An open-labelled study. Respir. Med.. 2006;100 2160–2169. doi:10.1016/j.rmed.2006.03.015
336. Drager L.F., Bortolotto L.A., Figueiredo A.C., Krieger E.M., Lorenzi G.F.. Effects of continuous positive airway pressure on early signs of atherosclerosis in obstructive sleep apnea. Am. J. Respir. Crit. Care Med.. 2007;176 706–712. doi:10.1164/rccm.200703-500OC
337. Nadeem R., Singh M., Nida M., Kwon S., Sajid H., Witkowski J., et al.. Effect of CPAP treatment for obstructive sleep apnea hypopnea syndrome on lipid profile: A meta-regression analysis. J. Clin. Sleep Med.. 2014;10 1295–1302. doi:10.5664/jcsm.4282
338. Xu H., Yi H., Guan J., Yin S.. Effect of continuous positive airway pressure on lipid profile in patients with obstructive sleep apnea syndrome: A meta-analysis of randomized controlled trials. Atherosclerosis. 2014;234 446–453. doi:10.1016/j.atherosclerosis.2014.03.034
339. Lin M.T., Lin H.H., Lee P.L., Weng P.H., Lee C.C., Lai T.C., et al.. Beneficial effect of continuous positive airway pressure on lipid profiles in obstructive sleep apnea: A meta-analysis. Sleep Breath. 2015;19 809–817. doi:10.1007/s11325-014-1082-x
340. Chen B., Guo M., Peker Y., Salord N., Drager L.F., Lorenzi-Filho G., et al.. Effect of Continuous Positive Airway Pressure on Lipid Profiles in Obstructive Sleep Apnea: A Meta-Analysis. J. Clin. Med.. 2022;11 doi:10.3390/jcm11030596
341. Cholidou K.G., Kostakis I.D., Manali E.D., Perrea D., Margeli A., Vougas K., et al.. Calprotectin: A protein related to cardiovascular risk in adult patients with obstructive sleep apnea. Cytokine. 2013;61 917–923. doi:10.1016/j.cyto.2012.12.014
342. Chen B., Somers V.K., Tang X., Li Y.. Moderating Effect of BMI on the Relationship Between Sympathetic Activation and Blood Pressure in Males with Obstructive Sleep Apnea. Nat. Sci. Sleep. 2021;13 339–348. doi:10.2147/NSS.S297707
343. Schmoller A., Eberhardt F., Jauch-Chara K., Schweiger U., Zabel P., Peters A., et al.. Continuous positive airway pressure therapy decreases evening cortisol concentrations in patients with severe obstructive sleep apnea. Metabolism. 2009;58 848–853. doi:10.1016/j.metabol.2009.02.014
344. Shang W., Zhang Y., Wang G., Han D.. Benefits of continuous positive airway pressure on glycaemic control and insulin resistance in patients with type 2 diabetes and obstructive sleep apnoea: A meta-analysis. Diabetes Obes. Metab.. 2021;23 540–548. doi:10.1111/dom.14247
345. Koenig A.M., Koehler U., Hildebrandt O., Schwarzbach H., Hannemann L., Boneberg R., et al.. The Effect of Obstructive Sleep Apnea and Continuous Positive Airway Pressure Therapy on Skeletal Muscle Lipid Content in Obese and Nonobese Men. J. Endocr. Soc.. 2021;5 bvab082. doi:10.1210/jendso/bvab082
346. Chopra S., Rathore A., Younas H., Pham L.V., Gu C., Beselman A., et al.. Obstructive Sleep Apnea Dynamically Increases Nocturnal Plasma Free Fatty Acids, Glucose, and Cortisol During Sleep. J. Clin. Endocrinol. Metab.. 2017;102 3172–3181. doi:10.1210/jc.2017-00619
347. Fadaei R., Koushki M., Sharafkhaneh A., Moradi N., Ahmadi R., Rostampour M., et al.. The impact of continuous positive airway pressure therapy on circulating levels of malondialdehyde: A systematic review and meta-analysis. Sleep Med.. 2020;75 27–36. doi:10.1016/j.sleep.2020.02.014
348. Akinnusi M.E., Laporta R., El-Solh A.A.. Lectin-like oxidized low-density lipoprotein receptor-1 modulates endothelial apoptosis in obstructive sleep apnea. Chest. 2011;140 1503–1510. doi:10.1378/chest.11-0302
349. Chirinos J.A., Gurubhagavatula I., Teff K., Rader D.J., Wadden T.A., Townsend R., et al.. CPAP, weight loss, or both for obstructive sleep apnea. N. Engl. J. Med.. 2014;370 2265–2275. doi:10.1056/NEJMoa1306187
350. Ramar K., Dort Leslie C., Katz Sheri G., Lettieri Christopher J., Harrod Christopher G., Thomas Sherene M., et al.. Clinical Practice Guideline for the Treatment of Obstructive Sleep Apnea and Snoring with Oral Appliance Therapy: An Update for 2015. J. Clin. Sleep Med.. 2015;11 773–827. doi:10.5664/jcsm.4858
351. Recoquillon S., Pépin J.L., Vielle B., Andriantsitohaina R., Bironneau V., Chouet-Girard F., et al.. Effect of mandibular advancement therapy on inflammatory and metabolic biomarkers in patients with severe obstructive sleep apnoea: A randomised controlled trial. Thorax. 2019;74 496–499. doi:10.1136/thoraxjnl-2018-212609
352. Venema J., Vries G.E.K., van Goor H., Westra J., Hoekema A., Wijkstra P.J.. Cardiovascular and metabolic effects of a mandibular advancement device and continuous positive airway pressure in moderate obstructive sleep apnea: A randomized controlled trial. J. Clin. Sleep Med.. 2022;18 1547–1555. doi:10.5664/jcsm.9908
353. Silva L., Guimarães T.M., Pontes G., Coelho G., Badke L., Fabbro C.D., et al.. The effects of continuous positive airway pressure and mandibular advancement therapy on metabolic outcomes of patients with mild obstructive sleep apnea: A randomized controlled study. Sleep Breath. 2021;25 797–805. doi:10.1007/s11325-020-02183-1
354. Li L., Zhan X., Wang N., Pinto J.M., Ge X., Wang C., et al.. Does airway surgery lower serum lipid levels in obstructive sleep apnea patients? A retrospective case review. Med. Sci. Monit.. 2014;20 2651–2657. doi:10.12659/MSM.892230
355. She W., Wang J., Qian X., Hang M.. Long-term follow-up of patients with obstructive sleep apnea syndrome treated with uvulopalatopharyngoplasty. Zhonghua Er Bi Yan Hou Ke Za Zhi. 2001;36 227–230.
356. Bikov A., Frent S., Reisz D., Negru A., Gaita L., Breban Schwarzkopf D., et al.. Comparison of Composite Lipid Indices in Patients with Obstructive Sleep Apnoea. Nat. Sci. Sleep. 2022;14 1333–1340. doi:10.2147/NSS.S361318

Where this page came from

This page was imported from Biomedicines (PubMed Central). “Obstructive Sleep Apnoea and Lipid Metabolism: The Summary of Evidence and Future Perspectives in the Pathophysiology of OSA-Associated Dyslipidaemia” by Martina Meszaros, Andras Bikov, Biomedicines (2022), doi:10.3390/biomedicines10112754, published under CC BY 4.0. Changed here: set as a page from the journal’s XML, its supplementary files left out; figures the article marks as reproduced under other terms are left out.

Nobody has written it yet — it is the source material at a new address, which is why search engines are asked to skip it and why no one earns from it. It is up for grabs: take it on, and it is yours to rewrite and to earn from.